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ABSTRACT	  
PHARMACOLOGICAL	  CHAPERONING	  IN	  FABRY	  DISEASE	  
SEPTEMBER	  2011	  
JEROME	  J.	  ROGICH,	  B.S.,	  UNIVERSITY	  OF	  MASSACHUSETTS	  AMHERST	  
M.S.,	  UNIVERSITY	  OF	  MASSACHUSETTS	  AMHERST	  
Directed	  by:	  Professor	  Scott	  C.	  Garman	  
	  
	   Fabry	  Disease	  is	  an	  X-­‐linked	  lysosomal	  storage	  disorder	  characterized	  by	  a	  variety	  
of	  symptoms	  including	  hypohydrosis,	  seizures,	  cardiac	  abnormalities,	  skin	  lesions,	  and	  
chronic	  pain.	  These	  symptoms	  stem	  from	  a	  lack	  of	  functional	  endogenous	  α-­‐
Galactosidase	  A	  (α-­‐GAL),	  which	  leads	  to	  an	  accrual	  of	  its	  natural	  substrate.	  The	  severity	  
of	  the	  disease	  symptoms	  can	  be	  directly	  correlated	  with	  the	  amount	  of	  residual	  enzyme	  
activity.	  
	   It	  has	  been	  shown	  that	  an	  imino	  sugar,	  1-­‐deoxygalactonojirimycin	  (DGJ),	  can	  
increase	  enzymatic	  activity	  and	  clear	  excess	  substrate.	  This	  pH-­‐dependent	  chaperoning	  
phenomenon	  is	  believed	  to	  arise	  from	  the	  presence	  of	  aspartic	  acid	  170	  in	  the	  active	  
site.	  This	  key	  residue	  may	  become	  protonated	  at	  lower	  pH,	  preventing	  a	  buried	  salt	  
bridge	  from	  being	  formed.	  We	  mutated	  this	  residue	  to	  an	  alanine,	  abolishing	  activity,	  
and	  making	  traditional	  assays	  impractical.	  We	  have	  measured	  the	  KD	  of	  chaperone	  for	  
this	  modified	  active	  site	  through	  crystallography.	  
	   Previous	  crystallographic	  studies	  on	  this	  enzyme	  have	  also	  shown	  a	  preliminary	  
second	  binding	  site	  on	  the	  surface	  of	  α-­‐Galactosidase	  that	  prefers	  the	  β-­‐Galactose	  
	  vii	  
anomer.	  When	  β-­‐Galactose	  binds	  it	  buries	  a	  greater	  surface	  area	  than	  when	  α-­‐galactose	  
binds	  to	  the	  active	  site.	  Binding	  of	  this	  site	  by	  a	  small	  molecule	  should	  stabilize	  the	  
native	  state	  of	  the	  enzyme,	  but	  would	  be	  sterically	  occluded	  from	  inhibiting	  active	  site.	  
We	  have	  probed	  this	  second	  site	  by	  soaking	  crystals	  of	  α-­‐Galactosidase	  with	  a	  small	  
library	  of	  compounds.	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CHAPTER	  1	  
	  
INTRODUCTION	  
1.1.	  The	  Lysosome	  and	  Glycoside	  Hydrolases	  
The	  lysosome	  is	  a	  membrane-­‐enclosed,	  low-­‐pH	  organelle	  found	  in	  eukaryotic	  
cells	  that	  is	  responsible	  for	  the	  degradation	  of	  macromolecules.	  Once	  these	  
macromolecules	  are	  degraded,	  the	  cell	  can	  then	  reutilize	  these	  components.	  The	  
lysosome	  carries	  out	  this	  function	  by	  containing	  and	  using	  a	  number	  of	  proteins	  that	  
catabolize	  macromolecular	  substrates.	  The	  substrates	  include	  glycoproteins,	  glycolipids,	  
and	  other	  essential	  metabolites.	  These	  substrates	  are	  delivered	  to	  the	  lysosome	  either	  
by	  fusion	  with	  vacuoles	  or	  by	  directly	  engulfing	  the	  substrates,	  which	  are	  then	  digested.	  	  
After	  digestion,	  the	  products	  are	  able	  to	  pass	  through	  the	  lysosomal	  membrane	  and	  are	  
reused.2	  
The	  proteins	  that	  perform	  this	  essential	  recycling	  function	  of	  the	  cell	  belong	  to	  
many	  different	  classes	  of	  enzymes	  including	  lipases,	  glycosidases,	  and	  proteases.	  These	  
enzymes	  are	  translated	  by	  ribosomes	  and	  undergo	  extensive	  post-­‐translational	  
processing	  before	  being	  trafficked	  to	  the	  lysosome.17,	  19	  
The	  glycoproteins	  present	  in	  the	  lysosome	  are	  characterized	  by	  the	  attachment	  
of	  carbohydrates	  to	  either	  a	  hydroxyl	  group	  of	  serine	  or	  amide	  group	  of	  asparagine.34	  In	  
order	  for	  a	  lysosomal	  enzyme	  to	  function	  properly,	  the	  correct	  polypeptide	  sequence	  
must	  be	  translated,	  properly	  folded,	  quaternary	  structure	  formed,	  have	  the	  correct	  
	  2	  
sugar	  groups	  be	  attached,	  trimmed,	  recognized,	  and	  then	  be	  transported	  to	  its	  final	  
destination	  in	  the	  lysosome	  to	  carry	  out	  its	  function.	  If	  any	  steps	  in	  this	  pathway	  fail,	  or	  
the	  protein	  becomes	  misfolded	  due	  a	  mutation,	  it	  may	  result	  in	  a	  lysosomal	  storage	  
disorder.10	  
1.2.	  Lysosomal	  Storage	  Diseases	  
We	  are	  interested	  in	  the	  class	  of	  enzymes	  belonging	  to	  the	  Glycoside	  Hydrolase	  
family.	  These	  enzymes	  act	  in	  a	  sequence	  in	  order	  to	  break	  down	  the	  glycosidic	  bonds	  
between	  the	  polymeric	  substrate.	  	  
Mutations	  in	  the	  human	  GLA	  gene	  encoding	  the	  polypeptide	  can	  disrupt	  
lysosomal	  function.26	  This	  class	  of	  disorders	  is	  interesting	  because	  symptoms	  of	  a	  
disease	  can	  be	  traced	  to	  the	  loss	  of	  a	  single	  enzyme.	  Substrate	  degradation	  in	  the	  
lysosome	  is	  a	  step-­‐wise	  process,	  with	  one	  enzyme’s	  product	  serving	  as	  another	  
enzyme’s	  substrate.15	  In	  humans	  there	  are	  about	  40	  of	  these	  diseases.13	  
1.3.	  Fabry	  Disease	  Results	  From	  α-­‐galactosidase	  Deficiency	  
	  	   Lysosomal	  storage	  diseases	  	  (LSD’s)	  are	  unique	  in	  that	  the	  build-­‐up	  of	  a	  particular	  
substrate	  is	  due	  to	  the	  lack	  of	  functional	  enzyme	  that	  is	  responsible	  for	  the	  degradation.	  
One	  LSD	  that	  our	  lab	  focuses	  on	  is	  Fabry	  Disease,	  which	  results	  from	  the	  lack	  of	  the	  
enzyme	  α-­‐galactosidase	  (α-­‐GAL).13	  This	  disorder	  is	  X-­‐linked	  recessive	  and	  affects	  
hydrolytic	  activity	  in	  nearly	  all	  tissues	  of	  the	  affected	  individual.36	  This	  specific	  enzyme	  is	  
encoded	  by	  the	  GLA	  gene	  and	  is	  responsible	  for	  the	  degradation	  of	  neutral,	  terminal	  α-­‐
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galactosylated	  substrates.17	  The	  most	  significant	  of	  these	  substrates	  is	  
globotriaosylceramide	  (GB3).4	  In	  classically	  affected	  patients,	  characterized	  by	  little	  or	  
no	  residual	  enzyme	  activity,	  this	  substrate	  leads	  to	  eventual	  organ	  failure	  and	  death	  if	  
left	  untreated.23	  Manifestations	  of	  this	  disease	  include	  angiokeratoma,	  hypohidrosis,	  
corneal	  opacities,	  acroparethesia,	  and	  vascular	  degradation	  of	  the	  neuronal,	  renal,	  and	  
cardiac	  tissues.26,30	  Other	  patients	  exhibit	  moderate	  residual	  activity	  and	  exhibit	  
symptoms	  that	  are	  limited	  to	  cardiac	  and/or	  renal	  tissues.19	  Decreased	  levels	  of	  α-­‐
galactosidase	  have	  been	  linked	  to	  an	  increased	  chance	  of	  developing	  left	  ventricular	  
hypertrophy,	  and	  individuals	  retain	  about	  5-­‐10%	  of	  endogenous	  activity.14	  As	  many	  as	  
3%	  of	  men	  suffering	  from	  hypertrophic	  cardiomyopathies	  can	  be	  linked	  to	  α-­‐GAL	  
deficiency.19	  
1.4.	  Overview	  of	  Structure	  and	  Active	  Site	  
	  	   The	  structure	  of	  human	  α-­‐galactosidase	  was	  initially	  solved	  by	  x-­‐ray	  
crystallography	  in	  2004.18	  The	  structure	  reveals	  a	  protein	  homodimer	  (Figure	  1)	  in	  which	  
each	  monomer	  is	  composed	  of	  two	  domains.	  The	  domain	  containing	  the	  catalytic	  
activity	  begins	  at	  residue	  32	  and	  extends	  to	  residue	  330.	  This	  chain	  folds	  into	  a	  (β/α)8	  
barrel,	  which	  is	  also	  known	  as	  a	  TIM	  barrel.	  The	  residues	  331-­‐429	  fold	  into	  a	  β-­‐sandwich	  
domain,	  which	  packs	  against	  the	  first	  domain,	  burying	  2200	  Å2of	  surface	  area.	  There	  is	  
no	  known	  function	  of	  this	  domain.	  
	  	   The	  active	  sites	  of	  each	  monomer	  are	  separated	  by	  50	  Å.	  The	  active	  site	  of	  α-­‐
galactosidase	  consists	  of	  15	  residues	  from	  7	  loops	  of	  the	  TIM	  barrel	  (Figure	  3).	  These	  
	  4	  
residues	  are	  D170,	  D231,	  W47,	  D92,	  D93,	  Y134,	  K168,	  E203,	  L206,	  Y207,	  R227,	  D266,	  
and	  M267.	  The	  final	  two	  residues,	  are	  C142	  and	  C172	  are	  involved	  in	  a	  disulfide	  bond.5	  
Twelve	  of	  the	  fifteen	  residues	  are	  conserved	  among	  other	  hydrolases	  of	  this	  family.	  The	  
remaining	  three	  residues	  vary	  between	  other	  related	  enzymes	  to	  allow	  the	  overall	  fold	  
of	  the	  active	  site	  to	  remain	  the	  same	  while	  allowing	  different	  substrates	  to	  be	  bound.17	  	  
	  	   Upon	  binding	  substrate,	  the	  protein	  makes	  polar	  contacts	  with	  every	  functional	  
group	  of	  the	  galactose	  monosaccharide.	  There	  are	  also	  significant	  van	  der	  Waals	  
interactions	  between	  W47	  and	  the	  terminal	  galactose	  moiety,	  causing	  the	  sugar	  to	  stack	  
along	  the	  hydrophobic	  face	  of	  the	  residue.18	  A	  pair	  of	  aspartic	  acid	  residues	  act	  as	  a	  
nucleophile	  and	  acid/base	  in	  this	  enzyme,	  which	  function	  according	  to	  Koshland’s	  classic	  
double	  displacement	  mechanism.27	  This	  mechanism	  retains	  the	  configuration	  of	  the	  
anomeric	  carbon	  while	  breaking	  the	  glycosidic	  bond	  between	  α-­‐galactose	  and	  the	  
aglycone	  portion	  of	  substrate.	  
	  	   The	  carboxylates	  of	  the	  D170	  and	  D231	  carry	  out	  this	  reaction	  by	  fulfilling	  two	  
different	  roles.	  Koshland’s	  originally	  proposed	  mechanism	  requires	  one	  residue	  to	  
perform	  a	  nucleophilic	  attack	  and	  the	  second	  to	  act	  as	  an	  acid/base.	  Upon	  binding	  of	  the	  
substrate,	  D170	  attacks	  and	  breaks	  the	  glycosidic	  linkage.	  After	  this	  initial	  step,	  the	  
aspartic	  acid	  is	  transiently	  covalently	  bound	  to	  the	  substrate,	  which	  is	  in	  a	  high-­‐energy	  
twist	  boat	  conformation.21	  The	  covalent	  acyl	  enzyme-­‐intermediate	  is	  released	  when	  
D231	  deprotonates	  a	  water	  molecule	  and	  a	  lone	  pair	  of	  the	  water	  attacks	  the	  covalent	  
intermediate,	  leading	  to	  release	  of	  the	  product	  from	  the	  enzyme.	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1.5.	  Current	  Treatments	  for	  Fabry	  Disease	  
	  	   In	  Fabry	  Disease,	  there	  have	  been	  many	  proposed	  methods	  of	  therapy	  including	  
bone	  marrow	  transplantation,28	  substrate	  reduction	  therapy,1	  enzyme	  replacement	  
therapy,11,12	  stem	  cell	  therapy,37	  and	  pharmacological	  chaperone	  therapy.39	  The	  only	  
currently	  approved	  treatment	  for	  the	  treatment	  of	  Fabrazyme	  is	  Enzyme	  Replacement	  
Therapy	  (ERT).	  This	  treatment	  consists	  of	  recombinant	  enzyme,	  which	  is	  delivered	  via	  IV	  
infusion	  repeatedly	  throughout	  the	  course	  of	  treatment.	  This	  form	  of	  treatment	  is	  
offered	  in	  the	  form	  of	  Fabrazyme	  (Genzyme	  Inc.),	  and	  Replagal	  (Shire).	  	  
1.6.	  Pharmacological	  Chaperone	  Therapy	  (PCT)	  
	  	   It	  has	  been	  shown	  that	  the	  enzyme’s	  natural	  product	  galactose	  stabilizes	  various	  
mutations	  in	  COS	  cells	  as	  well	  as	  in	  patients	  through	  infusion	  therapy.16,39	  This	  galactose-­‐
stabilized	  enzyme	  was	  better	  trafficked	  to	  the	  lysosome,	  and	  led	  to	  an	  increase	  in	  
overall	  α-­‐galactosidase	  activity.39	  This	  result	  provided	  a	  basis	  for	  later	  research	  on	  
pharmacological	  chaperone	  therapies,	  in	  which	  a	  small	  molecule	  that	  has	  the	  ability	  to	  
chaperone	  a	  potentially	  misfolded	  protein	  upon	  binding.	  This	  may	  help	  the	  protein	  
properly	  fold,	  escape	  ER	  Associated	  Degradation	  (ERAD)	  and	  traffic	  to	  lysosome.13	  Even	  
just	  5%	  -­‐	  10%	  of	  the	  normal	  level	  of	  enzyme	  activity	  is	  enough	  to	  prevent	  the	  classical	  
symptoms	  of	  Fabry	  Disease	  caused	  by	  the	  build-­‐up	  of	  toxic	  substrates.18	  
Pharmacological	  chaperones	  that	  are	  specifically	  targeted	  to	  bind	  at	  the	  active	  site	  of	  
the	  enzyme	  are	  also	  known	  as	  Active	  Site	  Specific	  Chaperones	  (ASSC).15	  However,	  this	  
effect	  was	  only	  present	  at	  extremely	  high	  concentrations	  of	  galactose.39	  Studies	  have	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since	  improved	  on	  the	  chaperoning	  effect	  initially	  seen	  by	  galactose	  by	  utilizing	  different	  
families	  of	  compounds	  that	  bind	  more	  tightly	  to	  the	  active	  site.38	  	  
1.7.	  Characteristics	  of	  a	  PCT	  
	   Because	  many	  PCT’s	  are	  specifically	  targeted	  toward	  the	  active	  site,	  there	  are	  a	  
number	  of	  design	  elements	  that	  must	  be	  accounted	  for	  while	  sorting	  through	  
compounds	  that	  may	  serve	  as	  a	  PCT.	  The	  first	  characteristic	  of	  a	  pharmacological	  
chaperone	  is	  to	  have	  a	  high	  affinity	  for	  the	  protein.	  For	  this	  reason,	  enzyme	  inhibitors	  
can	  serve	  as	  chaperones	  below	  inhibitory	  concentrations.	  The	  compound	  must	  also	  be	  
able	  to	  permeate	  the	  cellular	  membrane	  and	  reach	  the	  ER,	  where	  it	  can	  function	  as	  a	  
folding	  chaperone.	  Increased	  permeability	  allows	  the	  compound	  to	  be	  more	  potent	  at	  
lower	  concentrations,	  avoiding	  potential	  side	  effects.15	  
Once	  a	  chaperone	  has	  carried	  out	  its	  function	  of	  increasing	  the	  percentage	  of	  
folded	  protein,	  it	  must	  dissociate.	  If	  the	  compound	  were	  to	  stay	  bound,	  the	  protein	  
would	  not	  be	  able	  to	  carry	  out	  physiological	  function.29	  
1.8.	  The	  Mechanism	  of	  1-­‐deoxygalactonojirimycin	  (DGJ)	  
	   A	  promising	  chaperone	  candidate	  for	  the	  treatment	  of	  Fabry	  Disease	  is	  1-­‐
deoxygalactonojirimycin	  (DGJ)	  (Figure	  2).	  It	  is	  a	  member	  of	  the	  imino	  sugar	  family	  of	  
compounds.	  It	  was	  found	  that	  this	  tight	  binding	  inhibitor	  increased	  enzymatic	  activity	  in	  
patient	  lymphoblasts	  and	  fibroblasts.13,41	  The	  IC50	  of	  this	  ligand	  toward	  α-­‐galactosidase	  
is	  approximately	  50nM.13	  Weaker	  binding	  imino	  sugars	  of	  the	  same	  family	  were	  not	  as	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efficacious	  in	  chaperoning	  α-­‐GAL.4	  Our	  group	  has	  previously	  shown	  that	  this	  tight	  
binding	  comes	  predominately	  from	  a	  buried	  salt-­‐bridge.21	  This	  bond	  consists	  of	  the	  
deprotonated	  negatively	  charged	  carboxylate	  of	  aspartic	  acid	  170	  and	  the	  positively	  
charged	  secondary	  amine	  present	  in	  the	  pyridine	  ring.	  DGJ	  is	  also	  a	  promising	  candidate	  
for	  a	  PCT	  because	  it	  behaves	  differently	  at	  various	  physiological	  pH’s.	  The	  ER	  is	  the	  
organelle	  in	  which	  proteins	  are	  synthesized	  and	  processed.	  It	  maintains	  a	  pH	  of	  
approximately	  7.2,	  and	  it	  is	  at	  this	  pH	  that	  DGJ	  must	  be	  able	  to	  successfully	  chaperone	  
misfolded	  protein.	  With	  a	  pKa	  of	  3.9,	  the	  aspartic	  acid	  side	  chain	  is	  largely	  deprotonated	  
at	  neutral	  pH,	  and	  the	  salt	  bridge	  can	  be	  formed.	  As	  previously	  mentioned,	  the	  
inhibitory	  chaperone	  must	  be	  able	  to	  dissociate	  from	  the	  protein	  in	  order	  for	  it	  to	  
correctly	  carry	  out	  its	  biological	  function.	  If	  the	  protein	  is	  correctly	  folded,	  it	  is	  
transported	  to	  the	  lysosome	  via	  the	  Mannose-­‐6-­‐Phosphate	  receptor.	  The	  acidic	  
lysosome	  exhibits	  a	  pH	  of	  ~4.5,	  where	  aspartic	  acid	  170	  protonates	  and	  becomes	  
neutrally	  charged.	  DGJ	  binds	  more	  weakly	  in	  the	  absence	  of	  the	  salt	  bridge	  and	  DGJ	  can	  
be	  released	  from	  the	  active	  site.	  
1.9.	  Potential	  for	  Inhibition	  of	  Other	  Lysosomal	  Enzymes	  
	  	   Human	  α-­‐galactosidase	  does	  not	  act	  alone	  in	  the	  lysosome.	  It	  is	  just	  one	  of	  
approximately	  fifty	  acid	  hydrolases	  that	  act	  in	  the	  lysosome.	  The	  same	  competitive	  
inhibitor	  that	  may	  chaperone	  one	  protein	  may	  bind	  to	  an	  off-­‐target	  enzyme.	  If	  the	  
enzyme	  becomes	  inhibited,	  it	  may	  generate	  symptoms	  of	  a	  different	  LSD	  in	  the	  patient.	  
This	  potential	  issue	  has	  not	  been	  thoroughly	  studied.	  The	  enzyme	  α-­‐N-­‐
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acetylgalactosaminidase	  (α-­‐NAGAL),	  is	  a	  lysosomal	  enzyme	  that	  is	  responsible	  for	  
cleaving	  terminal	  α-­‐linked	  N-­‐acetyl-­‐galactosaminide	  substrates.	  The	  proteins	  are	  46%	  
identical	  and	  the	  active	  sites	  of	  α-­‐GAL	  and	  α-­‐NAGAL	  are	  similar,	  and	  share	  13	  of	  the	  15	  
active	  site	  residues.	  If	  α-­‐NAGAL	  were	  to	  become	  inhibited	  by	  DGJ,	  we	  predict	  it	  would	  
induce	  symptoms	  of	  Schindler	  disease,	  which	  include	  seizures	  and	  neurological	  
degeneration.17	  
1.10.	  Project	  Significance	  and	  Goals	  
This	  thesis	  describes	  the	  investigation	  of	  a	  ligand	  binding	  site	  on	  α-­‐GAL	  distal	  
from	  the	  active	  site.21	  We	  have	  soaked	  crystals	  of	  α-­‐GAL	  with	  a	  variety	  of	  compounds	  in	  
order	  to	  determine	  whether	  this	  site	  would	  be	  useful	  as	  a	  PCT	  binding	  site.	  
The	  second	  part	  of	  this	  thesis	  describes	  the	  interrogation	  of	  specific-­‐binding	  and	  
pharmacological	  chaperoning	  activity	  of	  DGJ	  through	  crystallography.	  By	  mutating	  the	  
catalytic	  nucleophile	  D170	  to	  an	  alanine,	  we	  observed	  that	  affinity	  decreased	  
significantly,	  due	  to	  the	  removal	  of	  the	  salt-­‐bridge	  between	  the	  protein	  and	  DGJ.	  Further	  
interrogating	  the	  strength	  of	  this	  interaction	  may	  provide	  insight	  that	  will	  be	  useful	  in	  
the	  rational	  design	  of	  future	  pharmacological	  chaperones	  for	  the	  treatment	  of	  protein	  
folding	  disorders.	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   CHAPTER	  2	  
	  
STUDIES	  ON	  THE	  2nd	  BINDING	  SITE	  OF	  α-­‐GALACTOSIDASE	  
2.1.	  Previously	  Established	  Work	  
	  	   There	  are	  currently	  15	  crystal	  structures	  of	  human	  α-­‐galactosidase	  in	  the	  Protein	  
Data	  Bank,	  and	  a	  number	  of	  those	  contain	  ligands	  bound	  to	  a	  second	  binding	  site,	  
including	  the	  structures	  3HG2,	  3HG3,	  3HG5,	  3LXA,	  3LXB,	  3LXC,	  3S5Y	  and	  3X5Z.	  In	  many	  
cases	  β-­‐galactose	  is	  bound	  to	  the	  second	  binding	  site	  on	  the	  surface	  of	  α-­‐galactosidase.	  
The	  saccharide	  packs	  on	  the	  surface	  of	  Tyrosine	  329	  and	  makes	  two	  hydrogen	  bonds	  
with	  the	  residues	  Aspartic	  Acid	  255	  and	  Lysine	  374	  (Figure	  5).	  While	  the	  active	  site	  is	  
specific	  for	  α	  anomers	  of	  galactose,	  the	  β	  anomer	  is	  preferred	  at	  the	  second	  site.	  The	  
paper	  initially	  reporting	  this	  phenomenon	  also	  states	  this	  binding	  is	  seen	  only	  at	  high	  
concentrations	  of	  cryoprotectant	  sugars	  (15%	  lactose,	  100mM	  melibiose,	  20%	  galactose,	  
20%	  glucose).21	  
	  	   β-­‐galactose	  binding	  buries	  more	  protein	  surface	  area	  at	  the	  second	  site,	  157	  Å2,	  
than	  the	  104	  Å2	  that	  is	  buried	  upon	  the	  α-­‐galactose	  binding	  to	  the	  active	  site.20	  We	  
hypothesize	  that	  this	  site	  could	  be	  a	  promising	  candidate	  for	  pharmacological	  
chaperone	  therapy.	  Since	  both	  sites	  exhibit	  selectivity	  towards	  the	  ligand	  they	  bind,	  it	  
may	  be	  possible	  to	  rationally	  design	  a	  sugar	  that	  binds	  specifically	  to	  the	  2nd	  site.	  This	  
would	  be	  advantageous	  over	  current	  candidates	  for	  chaperone	  therapy	  because	  there	  
would	  be	  little	  chance	  of	  the	  chaperoning	  inhibiting	  an	  off-­‐target	  enzyme.	  In	  order	  to	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characterize	  this	  second	  site,	  we	  decided	  to	  soak	  crystals	  of	  α-­‐galactosidase	  with	  a	  
library	  of	  fragments	  with	  the	  intent	  of	  probing	  binding	  site	  for	  fragments	  that	  could	  be	  
added	  as	  moieties	  to	  a	  monosaccharide	  backbone.	  	  
2.2.	  Fabrazyme	  Crystal	  Growth	  
	  	   Protein	  to	  be	  crystallized	  was	  a	  gift	  from	  the	  Genzyme	  Corporation.	  Recombinant	  
α-­‐galactosidase	  produced	  by	  Genzyme	  for	  enzyme	  replacement	  therapy	  is	  known	  by	  its	  
trade	  name,	  Fabrazyme.	  The	  protein	  arrived	  at	  a	  concentration	  of	  ~6mg/mL	  and	  was	  
placed	  in	  hanging-­‐drop	  trays.	  Known	  conditions	  for	  the	  crystallization	  of	  Fabrazyme	  are	  
20%	  PEG	  4K,	  0.2M	  Ammonium	  Sulfate,	  0.1M	  Sodium	  Acetate	  pH	  4.6.21	  The	  best-­‐formed	  
crystals	  grew	  at	  room	  temperature	  after	  three	  days.	  Varying	  the	  ratio	  of	  protein	  and	  
mother	  liquor	  led	  to	  the	  largest	  isolated	  crystals	  forming	  at	  a	  ratio	  of	  2:1	  protein	  to	  
mother	  liquor	  (Figure	  4).	  Smaller	  crystals	  were	  crushed	  and	  micro-­‐seeded	  into	  wells	  
containing	  a	  2:1	  ratio	  of	  protein	  and	  mother	  liquor,	  but	  diffraction	  quality	  crystals	  did	  
not	  form.	  Subsequent	  trials	  using	  4µL	  of	  protein	  and	  2µL	  of	  mother	  liquor	  resulted	  in	  
crystals	  as	  large	  as	  500µm	  in	  the	  longest	  direction.	  	  
2.3.	  Chemical	  Library	  
	  	   The	  library	  chosen	  for	  our	  small	  molecule	  soaks	  examining	  the	  second	  site	  
contains	  a	  variety	  of	  small	  molecules	  that	  were	  included	  based	  on	  their	  ability	  to	  
stabilize	  intermolecular	  interactions.	  Hampton	  Research	  created	  the	  Silver	  Bullet	  kit	  
based	  on	  the	  ability	  of	  these	  small	  molecules	  to	  promote	  lattice	  formation,	  stabilize	  
protein	  conformation,	  and	  induce	  crystallization.	  These	  small	  molecules	  are	  from	  many	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different	  families	  including	  single	  amino	  acids,	  organic	  acids	  and	  salts,	  small	  peptides,	  
and	  carbohydrates.	  	  
	  	   Other	  rational	  molecules	  were	  chosen	  for	  chemical	  soaks	  that	  would	  replicate	  
and	  expand	  on	  previous	  findings.	  These	  molecules	  included	  D-­‐galactose,	  D-­‐glucose,	  
phenol,	  cyclohexanol,	  and	  a	  galactose	  and	  formic	  acid	  co-­‐soak.	  
2.4.	  SiteHound	  Binding	  Prediction	  	  
	   A	  model	  of	  α-­‐gal	  was	  uploaded	  to	  the	  SiteHound	  server,	  which	  was	  developed	  to	  
compute	  interactions	  between	  a	  chemical	  probe	  and	  a	  protein	  structure.22	  The	  program	  
was	  run	  with	  the	  selection	  to	  probe	  binding	  sites	  using	  a	  methyl	  carbon.	  The	  server	  also	  
generates	  a	  visualization	  script	  for	  PyMol.	  The	  most	  promising	  pockets	  are	  colored	  red,	  
with	  lowering	  scoring	  pockets	  further	  down	  the	  color	  spectrum	  toward	  violet.	  
	   The	  result	  from	  the	  SiteHound	  server	  showed	  that	  α-­‐gal	  did	  have	  a	  predicted	  
binding	  pocket	  above	  Tyrosine	  Y329,	  but	  it	  was	  not	  one	  of	  the	  more	  significant	  binding	  
sites.	  The	  predicted	  binding	  site	  was	  centered	  over	  the	  Y329,	  making	  full	  use	  of	  the	  
hydrophobic	  stacking	  interactions.	  Another	  predicted	  binding	  patch	  was	  calculated	  to	  
extend	  from	  the	  binding	  site	  surrounding	  Tyrosine	  329	  and	  continue	  between	  two	  α-­‐
helices	  of	  the	  TIM	  barrel,	  which	  could	  be	  used	  in	  rational	  design.	  Experimental	  results	  
show	  galactose	  binding	  to	  the	  2nd	  site	  not	  directly	  over	  the	  Tyrosine	  (Figure	  6).	  From	  this	  
observation,	  we	  hypothesized	  that	  phenol	  and	  cyclohexanol	  might	  bind	  to	  this	  location	  
on	  the	  protein.	  We	  predicted	  the	  rigidity	  of	  phenol	  would	  pack	  more	  tightly	  against	  the	  
tyrosine	  while	  cyclohexanol	  would	  be	  able	  to	  sample	  the	  many	  conformations	  that	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hexoses	  are	  able	  to	  obtain.	  Neither	  of	  the	  soaks	  and	  collections	  showed	  any	  binding	  to	  
the	  2nd	  site	  at	  a	  concentration	  of	  100mM.	  	  
2.5.	  Crystal	  Soaks	  	  
	   Crystals	  of	  Fabrazyme	  were	  harvested	  stepwise	  into	  30%	  PEG	  4K	  and	  20%	  
glycerol.	  Each	  well	  of	  the	  Silver	  Bullet	  screen	  contained	  three	  to	  nineteen	  compounds	  
and	  a	  buffer.	  In	  order	  to	  ensure	  proper	  cryoprotection,	  9uL	  of	  the	  cryoprotectant	  
containing	  the	  crystal	  was	  transferred	  to	  a	  glass	  slide	  using	  a	  pipette.	  One	  µL	  of	  one	  
soak	  condition	  of	  the	  Silver	  Bullet	  library	  was	  added	  to	  the	  9µL	  containing	  the	  crystal.	  
The	  mixture	  was	  then	  gently	  pipetted	  to	  mix,	  resulting	  in	  a	  final	  18%	  glycerol	  
concentration.	  Crystals	  were	  frozen	  in	  Liquid	  Nitrogen	  and	  transferred	  to	  a	  cryostream	  
at	  100°	  K	  for	  collection.	  	  
2.6.	  Data	  Collection	  
	   Preliminary	  collections	  were	  done	  in-­‐house	  using	  a	  Rigaku	  MSC	  RUH3R	  X-­‐ray	  
generator.	  The	  diffraction	  images	  were	  collected	  on	  a	  Raxis	  IV++	  image	  plate	  area	  
detector.	  Crystals	  were	  screened	  by	  diffraction	  images,	  and	  data	  sets	  collected	  on	  
suitable	  crystals.	  Fifteen	  minute	  exposures	  per	  degree	  were	  required	  in-­‐house	  in	  order	  
to	  observe	  an	  adequate	  diffraction	  image.	  In	  order	  to	  improve	  workflow,	  the	  remaining	  
collections	  were	  prepared	  and	  stored	  at	  liquid	  nitrogen	  temperature,	  transported	  to	  
Brookhaven	  National	  Laboratory,	  and	  collected	  on	  the	  X6A	  beam	  line.	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2.7.	  Data	  Processing	  and	  Refinement	  
	  	   The	  diffraction	  images	  were	  processed	  and	  integrated	  using	  HKL2000.31	  HKL2000	  
is	  able	  to	  index	  diffraction	  images	  and	  integrate	  the	  reflections	  from	  each.	  Using	  the	  
CCP4	  program	  “Truncate”	  it	  is	  possible	  to	  convert	  these	  intensities	  to	  structure	  factors.	  
Each	  structure	  factor	  must	  contain	  a	  ampltitude,	  which	  is	  proportional	  to	  intensity,	  and	  
phase.	  The	  phases	  of	  the	  reflection	  cannot	  be	  recorded	  on	  a	  2D	  detector	  yet	  must	  be	  
determined	  in	  order	  to	  obtain	  a	  model.	  	  
The	  solutions	  were	  phased	  using	  the	  Fourier	  Synthesis	  method	  with	  PDB	  entry	  
3HG2	  that	  had	  been	  stripped	  of	  solvent,	  ligands,	  and	  glycan	  atoms.	  Atomic	  models	  were	  
built	  using	  the	  program	  Coot.	  The	  model	  was	  refined	  using	  REFMAC5	  as	  part	  of	  the	  CCP4	  
suite.	  Ligands,	  solvent,	  and	  glycans	  were	  added	  back	  to	  the	  model	  using	  peaks	  from	  a	  Fo-­‐
Fc	  difference	  map.	  
2.8.	  Issues	  with	  the	  P3221	  Space	  Group	  
	  	   Crystals	  of	  Fabrazyme	  exhibited	  space	  group	  P3221	  symmetry.	  This	  high-­‐
symmetry	  space	  group	  is	  advantageous,	  because	  it	  contains	  a	  three-­‐fold	  symmetry	  axis,	  
which	  allows	  for	  higher	  redundancy	  of	  data	  collection	  in	  a	  small	  number	  of	  frames.	  
	  	   This	  space	  group	  also	  offered	  a	  number	  of	  challenges.	  These	  crystals	  diffracted	  
to	  high	  resolution,	  but	  the	  long	  c-­‐axis	  of	  the	  crystals	  created	  a	  closely	  spaced	  diffraction	  
pattern.	  Moving	  the	  detector	  away	  from	  the	  crystal	  allowed	  us	  to	  collect	  complete	  low	  
resolution	  data	  but	  also	  limited	  our	  over-­‐all	  resolution.	  The	  larger	  area	  of	  the	  ACSD	  Q10	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CCD	  detector	  at	  the	  X6A	  beam	  line	  allowed	  us	  to	  collect	  these	  crystals	  to	  their	  
diffraction	  limits.	  	  
	   After	  we	  had	  collected	  our	  first	  data	  set,	  a	  more	  critical	  issue	  with	  the	  P3221	  
space	  group	  became	  apparent.	  This	  crystal	  form	  contains	  a	  dimer	  in	  the	  asymmetric	  
unit,	  providing	  us	  with	  two	  independent	  views	  of	  each	  binding	  site,	  but	  on	  of	  them	  was	  
occluded	  by	  the	  crystal	  lattice	  (Figure	  7).	  We	  continued	  experiments	  on	  the	  P3221	  
crystals	  while	  also	  exploring	  crystallization	  conditions	  that	  would	  yield	  different	  space	  
groups.	  
	   The	  crystal	  structures	  solved	  in	  the	  presence	  of	  Silver	  Bullet	  compounds,	  
phenol,	  and	  cyclohexanol	  do	  not	  show	  any	  significant	  binding	  to	  the	  second	  site	  of	  α-­‐
galactosidase	  (Figure	  8).	  There	  is	  a	  small	  positive	  peak	  in	  the	  Fo-­‐Fc	  map	  in	  two	  of	  the	  
crystal	  soaks.	  This	  most	  likely	  corresponds	  to	  the	  ethylene	  glycol	  binding	  to	  the	  second	  
site,	  which	  we	  have	  seen	  previously	  in	  these	  conditions.	  
Crystal	  structures	  were	  also	  collected	  in	  the	  presence	  of	  high	  concentrations	  of	  
sugars	  in	  an	  attempt	  to	  replicate	  the	  initial	  findings.	  The	  soak	  protocol	  was	  modified	  to	  
include	  galactose	  directly	  in	  the	  cryoprotectant	  solution.	  This	  method	  also	  failed	  to	  
replicate	  the	  initial	  result.	  After	  no	  binding	  was	  seen	  when	  500mM	  of	  glucose	  was	  
added	  to	  the	  cryoprotectant,	  it	  was	  determined	  that	  the	  2nd	  binding	  site	  of	  α-­‐
galactosidase	  was	  of	  too	  low	  affinity	  to	  be	  used	  as	  a	  target	  for	  pharmacological	  
chaperone	  therapy.	  
2.9.	  Discussion	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   The	  small	  molecule	  1-­‐deoxygalactonojirmycin	  (DGJ)	  is	  a	  potent	  inhibitor	  of	  
human	  α-­‐galactosidase.	  At	  sub-­‐inhibitory	  concentrations	  it	  has	  the	  ability	  to	  serve	  as	  a	  
therapeutic	  treatment	  for	  the	  symptoms	  of	  Fabry	  Disease.	  It	  is	  hypothesized	  that	  DGJ	  
serves	  as	  a	  folding	  template	  for	  the	  mutant	  enzyme.	  The	  enzyme	  may	  be	  able	  to	  fold	  
around	  the	  chaperone	  into	  its	  native	  conformation.	  This	  would	  allow	  it	  to	  escape	  ERAD,	  
and	  allow	  it	  to	  be	  trafficked,	  increasing	  overall	  enzyme	  activity.	  However,	  its	  inhibitory	  
function	  may	  affect	  other	  lysosomal	  enzymes.	  The	  other	  enzyme	  of	  primary	  concern	  is	  
α-­‐N-­‐acetlygalactosaminidase	  (α-­‐NAGAL),	  has	  a	  very	  similar	  active	  site	  and	  can	  also	  bind	  
DGJ.40	  
The	  second	  site	  initially	  seemed	  like	  a	  site	  with	  an	  affinity	  for	  the	  β-­‐galactose.	  
Previous	  studies	  have	  shown	  carbohydrates	  and	  cryoprotectant	  bound	  over	  Tyrosine	  
away	  from	  the	  active	  site.	  It	  was	  hoped	  that	  this	  site	  could	  serve	  as	  a	  site	  for	  a	  novel	  
pharmacological	  chaperone	  to	  bind	  and	  its	  larger	  surface	  area	  could	  accompany	  a	  larger	  
ligand.	  This	  larger	  ligand	  would	  be	  excluded	  from	  the	  active	  sites	  of	  both	  enzyme,	  
avoiding	  the	  potential	  for	  inhibition	  for	  α-­‐GAL	  and	  α-­‐NAGAL.	  	  
The	  initial	  crystals	  collections	  suffered	  from	  high	  RSym	  factors	  as	  well	  as	  a	  low	  
limit	  of	  diffraction.	  We	  thought	  that	  this	  limited	  resolution	  could	  account	  for	  the	  lack	  of	  
positive	  peak	  in	  our	  Fo-­‐Fc	  map.	  To	  test	  this	  hypothesis	  the	  original	  map	  in	  which	  β-­‐
galactose	  was	  seen	  to	  bind	  was	  run	  in	  “review	  restraints”	  mode	  with	  a	  high	  resolution	  
limit	  of	  3.2	  Å(Figure	  8,A).	  This	  mode	  places	  particular	  restraints	  for	  ligands,	  disulfide	  
bonds,	  and	  modified	  residues,	  while	  calculating	  phases.	  This	  mode	  does	  not	  idealize	  the	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model.	  Even	  at	  this	  truncated	  resolution,	  the	  positive	  peak	  is	  still	  seen	  in	  the	  Fo-­‐Fc	  map.	  
	  	   The	  second	  hypothesis	  was	  there	  was	  insufficient	  time	  with	  the	  current	  soak	  
method	  for	  ligand	  to	  occupy	  the	  crystal.	  Two	  soaks	  of	  100mM	  D-­‐galactose	  were	  
collected.	  One	  was	  prepared	  by	  adding	  1µL	  to	  9µL	  or	  harvest	  solution	  as	  had	  been	  done	  
previously.	  The	  second	  collection	  was	  prepared	  with	  the	  ligand	  dissolved	  directly	  into	  
the	  cryoprotectant	  solution	  and	  the	  filtered.	  Neither	  of	  these	  soaks	  showed	  any	  positive	  
density	  above	  the	  Tyrosine	  329.	  
The	  final	  cryoprotectant	  solution	  contained	  30%	  Polyethylene	  Glycol	  4000,	  
200mM	  Ammonium	  Sulfate,	  100mM	  Sodium	  Acetate	  pH	  4.6,	  and	  20%	  glycerol.	  This	  
solution	  is	  extremely	  viscous	  and	  may	  take	  longer	  than	  the	  5	  minutes	  that	  was	  allowed	  
to	  reach	  equilibrium.	  Binding	  in	  high	  concentrations	  of	  sugars	  has	  been	  seen	  to	  occur	  in	  
as	  little	  as	  30	  seconds	  of	  soak	  time.35	  However,	  in	  the	  presence	  of	  viscous	  solutions	  (30%	  
PEG	  6K)	  crystals	  were	  soaked	  for	  two	  days	  in	  order	  to	  achieve	  binding.42	  
In	  order	  to	  improve	  the	  results	  of	  these	  soaks,	  I	  would	  attempt	  to	  test	  other	  
cryoprotectants	  that	  are	  not	  as	  viscous	  and	  would	  allow	  the	  crystal	  to	  equilibrate	  faster.	  
The	  ability	  of	  a	  number	  of	  solutions	  were	  tested	  for	  their	  ability	  to	  cryoprotect	  by	  
dipping	  a	  loop	  in	  the	  cryoprotectant	  solution,	  freezing	  it,	  and	  exposing	  it	  in-­‐house	  for	  15	  
seconds.	  	  
Another	  modification	  that	  may	  improve	  the	  results	  of	  the	  2nd	  Binding	  Studies	  
would	  be	  to	  provide	  agitation	  to	  the	  crystals	  while	  soaking	  them	  for	  a	  longer	  period	  of	  
	  17	  
time.	  Placing	  them	  in	  a	  larger	  volume	  of	  solution	  and	  allowing	  them	  to	  nutate	  for	  24-­‐28	  
hours	  will	  ensure	  full	  equilibration.	  
	  
	  18	  
	  	   	   	   	   	   CHAPTER	  3	  
	  
TITRATION	  OF	  PHARMACOLOGICAL	  CHAPERONE	  INTO	  D170A	  HUMAN	  α-­‐
GALACTOSIDASE	  
3.1.	  Previously	  Established	  Work	  
	  	   There	  are	  two	  structures	  of	  wild-­‐type	  α-­‐galactosidase	  bound	  with	  DGJ	  bound	  
(PDB	  codes	  3GXT	  and	  3S5Y).	  In	  each	  structure,	  both	  active	  sites	  are	  fully	  occupied	  by	  the	  
DGJ	  ligand.	  .	  Our	  lab	  is	  interested	  in	  the	  properties	  of	  the	  D170A	  mutant.21	  Not	  only	  
does	  this	  mutation	  render	  the	  enzyme	  inactive	  because	  it	  lacks	  the	  required	  catalytic	  
nucleophile,	  but	  it	  also	  disrupts	  a	  critical	  ionic	  interaction	  between	  the	  protein	  and	  
ligand.	  Many	  traditional	  methods	  for	  determining	  KD	  require	  the	  enzyme	  to	  be	  
functional.	  	  
Because	  KD	  determination	  based	  on	  activity	  is	  not	  possible	  in	  the	  D170A	  mutant,	  
we	  have	  examined	  a	  method	  for	  determining	  this	  KD	  through	  x-­‐ray	  crystallography.	  We	  
considered	  other	  methods	  for	  determining	  KD	  including	  isothermal	  calorimetry	  and	  
surface	  plasmon	  resonance.	  Isothermal	  calorimetry	  has	  the	  ability	  to	  provide	  a	  KD	  but	  
will	  not	  provide	  information	  on	  mechanism	  of	  binding	  of	  the	  ligand	  to	  the	  protein.	  
Surface	  plasmon	  resonance	  can	  also	  provide	  information	  about	  the	  KD	  but	  we	  were	  
concerned	  about	  crowding	  affects	  binding	  α-­‐GAL	  to	  the	  chip	  and	  the	  magnitude	  and	  
significance	  of	  the	  angle	  shift	  upon	  small	  molecule	  binding.	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Enzyme	  inhibition	  experiments	  have	  determined	  the	  Ki	  for	  DGJ	  and	  galactose	  to	  
be	  39nM	  and	  16mM	  respectively	  (Guce	  submitted)	  for	  the	  wild	  type	  enzyme.	  When	  
D170	  is	  mutated	  to	  an	  alanine,	  the	  chaperoning	  activity	  of	  DGJ	  becomes	  no	  better	  than	  
galactose.	  Our	  five	  crystal	  structures	  of	  the	  D170A	  mutant	  of	  α-­‐GAL	  titrated	  with	  
different	  amounts	  of	  DGJ	  support	  this	  conclusion.	  
3.2.	  Description	  of	  KD	  and	  Methods	  of	  Determination	  
	   The	  thermodynamic	  constant	  KD	  is	  useful	  because	  it	  provides	  a	  quantitative	  
determination	  of	  a	  complex’s	  propensity	  to	  dissociate	  into	  its	  individual	  subunits.	  A	  
related	  constant	  exists	  for	  association,	  the	  KA.	  It	  is	  described	  as	  the	  concentration	  of	  the	  
complex,	  [P•L],	  over	  the	  individual	  concentrations	  of	  free	  protein,	  [P],	  and	  free	  ligand	  
[L].	  
	  
KA	  =	  [P•L]	  /	  [P]•[L]	  	  
	   Since	  Equation	  1	  can	  satisfactorily	  describe	  association	  equilibrium,	  the	  inverse	  
holds	  true	  for	  the	  thermodynamics	  of	  dissociation.	  
KD	  =	  [P]•[L]	  /	  [P•L]	  
	   The	  equilibrium	  constants	  KA	  and	  KD	  can	  be	  determined	  experimentally.	  
Classically,	  these	  parameters	  are	  determined	  through	  activity	  or	  functional	  assays.	  Since	  
the	  D170A	  mutant	  protein	  lacks	  the	  catalytic	  nucleophile	  required	  to	  function,	  classical	  
enzymatic	  assays	  are	  not	  an	  option.	  Isothermal	  calorimetry	  or	  surface	  plasmon	  
resonance	  techniques	  have	  the	  ability	  to	  provide	  us	  with	  a	  KD	  .	  However,	  the	  signal	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would	  be	  small	  for	  a	  ligand	  in	  a	  Surface	  Plasmon	  Resonance	  experiment	  and	  ITC	  does	  
not	  provide	  information	  on	  the	  mechanism	  of	  binding.	  
3.3.	  D170A	  Crystal	  Growth	  
	   D170A	  α-­‐GAL	  protein	  was	  previously	  expressed	  and	  purified	  from	  insect	  cells	  by	  
Abigail	  Guce	  (University	  of	  Massachusetts	  Amherst).	  It	  was	  obtained	  at	  a	  concentration	  
of	  3	  mg/mL.	  The	  sample	  was	  concentrated	  to	  6.3	  mg/mL	  before	  crystallization	  trials.	  
Crystals	  were	  grown	  using	  the	  hanging-­‐drop	  diffusion	  method.	  These	  crystals	  grew	  in	  
reservoirs	  containing	  a	  mother	  liquor	  of	  15%	  -­‐	  22.5%	  Polyethylene	  Glycol	  4000,	  200mM	  
Ammonium	  Sulfate,	  and	  100mM	  Sodium	  Acetate	  pH	  4.6.	  The	  resulting	  crystals	  reached	  
their	  final	  size	  after	  3	  days	  at	  room	  temperature	  and	  exhibited	  the	  P3221	  space	  group.	  
The	  crystals	  ranged	  in	  size	  from	  ~100µm	  to	  ~300µm	  in	  the	  longest	  dimension	  with	  the	  
largest	  well-­‐formed	  crystals	  typically	  appearing2	  at	  15%	  PEG	  4K	  (Figure	  10).	  	  
3.4.	  Determination	  of	  D170A:DGJ	  Dissociation	  Constant	  Using	  Crystallography	  
	   In	  order	  to	  determine	  the	  dissociation	  constant	  KD	  through	  x-­‐ray	  crystallography,	  
crystals	  were	  soaked	  with	  different	  concentrations	  of	  pharmacological	  chaperone	  on	  a	  
logarithmic	  scale.	  Five	  structures	  of	  D170A	  α-­‐GAL	  were	  determined	  to	  various	  
resolutions.	  Each	  structure	  contained	  a	  different	  concentration	  of	  the	  pharmacological	  
chaperone	  DGJ.	  Based	  on	  pulse	  proteolysis	  and	  CD	  spectroscopic	  data,	  we	  hypothesized	  
the	  KD	  of	  DGJ	  for	  the	  D170A	  mutant	  to	  be	  on	  the	  order	  of	  millimolar	  (Guce	  submitted)	  
and	  soaked	  0mM,	  0.1mM,	  1mM,	  10mM,	  and	  100mM	  concentrations	  of	  DGJ	  into	  the	  
crystals.	  A	  number	  of	  cryoprotectants	  were	  tested	  by	  dipping	  an	  empty	  crystal	  mounting	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loop	  into	  a	  cryoprotectant,	  freezing	  it,	  and	  exposing	  it	  in	  the	  x-­‐ray	  beam	  for	  2	  minutes.	  
The	  harvest	  solution	  supplement	  with	  20%	  glycerol	  produces	  the	  image	  with	  the	  fewest	  
ice	  rings	  and	  was	  chosen	  as	  a	  cryoprotectant.	  Once	  the	  crystals	  were	  soaked	  in	  a	  ligand-­‐
containing	  solution	  for	  approximately	  5	  minutes,	  they	  were	  flash	  frozen	  in	  liquid	  
nitrogen.	  Crystals	  were	  exposed	  to	  x-­‐ray	  radiation	  at	  the	  NSLS	  X6A	  beam	  line	  and	  
diffraction	  images	  collected	  and	  processed	  using	  HKL2000.31	  Phases	  were	  obtained	  from	  
a	  previous	  structure	  in	  the	  same	  space	  group	  using	  the	  Fourier	  synthesis	  method.	  
Electron	  density	  maps	  were	  obtained,	  and	  atomic	  models	  built	  using	  Coot.9	  
	   A	  two	  state	  model	  was	  used	  to	  model	  the	  two	  fully	  occupied	  states	  of	  the	  
enzyme	  in	  accordance	  with	  previous	  literature.42	  When	  0mM	  of	  DGJ	  was	  added,	  glycerol	  
fully	  occupied	  the	  active	  site.	  With	  100mM	  of	  DGJ,	  the	  active	  site	  is	  fully	  occupied	  with	  
pharmacological	  chaperone.	  Ligands	  were	  built	  and	  refined	  for	  these	  two	  fully	  occupied	  
states	  (Figure	  11),	  then	  the	  atomic	  coordinates	  of	  both	  ligands	  were	  modeled	  into	  the	  
active	  site	  and	  refined	  against	  the	  10mM	  data.	  Eleven	  restrained	  refinements	  were	  
carried	  out	  with	  various	  occupancies	  for	  each	  ligand	  in	  10%	  increments	  (Figure	  12).	  
3.5.	  Attempt	  to	  Determine	  WT:DGJ	  Dissociation	  Constant	  Using	  Crystallography	  
	   The	  remaining	  crystals	  of	  α-­‐galactosidase	  that	  were	  previously	  grown	  for	  2nd	  
binding	  site	  studies	  were	  used	  in	  an	  attempt	  to	  confirm	  the	  dissociation	  constant	  of	  the	  
pharmacological	  chaperone	  for	  the	  wild	  type	  protein.	  A	  logarithmic	  series	  of	  
concentrations	  was	  chosen	  which	  including	  the	  following	  concentrations	  of	  chaperone:	  
0mM,	  10nM,	  100nM,	  1µM,	  100µM,	  and	  1mM.	  A	  50mM	  [DGJ]	  was	  also	  collected.	  The	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reported	  Ki	  is	  10-­‐40nM.	  
	   A	  different	  cryoprotectant	  was	  also	  chosen	  for	  this	  experiment.	  Glucose	  was	  
supplemented	  to	  the	  30%	  PEG	  4K	  harvest	  solution	  in	  order	  to	  provide	  cryoprotection.	  
Glucose	  would	  have	  provided	  a	  greater	  accuracy	  in	  KD	  determination	  because	  it	  is	  
sterically	  occluded	  from	  the	  active	  site.	  D-­‐glucose	  and	  D-­‐galactose	  are	  isomers,	  but	  they	  
differ	  in	  the	  arrangement	  of	  the	  hydroxyl	  group	  of	  carbon	  4.	  The	  hydroxyl	  in	  this	  
configuration	  cannot	  be	  accommodated	  by	  the	  active	  site,	  and	  does	  not	  bind.	  
The	  glycerol	  used	  in	  prior	  experiments	  acts	  as	  a	  competitive	  inhibitor	  and	  must	  
be	  expelled	  from	  the	  active	  site	  before	  DGJ	  can	  bind	  to	  the	  enzyme.	  Glycerol	  occupying	  
the	  active	  site	  will	  prevent	  DGJ	  from	  binding	  and	  the	  apparent	  KD	  will	  be	  slightly	  higher	  
than	  the	  true	  KD.	  
	   The	  protein	  crystals	  were	  harvested	  in	  30%	  PEG	  4K	  and	  moved	  step-­‐wise	  to	  a	  
solution	  containing	  30%	  PEG	  4K	  and	  20%	  glucose.	  The	  crystal	  was	  soaked	  in	  1mL	  of	  
ligand-­‐containing	  solution	  for	  5	  minutes	  while	  also	  being	  agitated	  with	  a	  pipette.	  The	  
purpose	  of	  the	  agitation	  was	  to	  ensure	  proper	  mixing	  and	  complete	  equilibration	  
between	  the	  protein	  and	  ligand	  in	  the	  viscous	  solution.	  The	  crystals	  were	  then	  flash	  
frozen	  in	  liquid	  nitrogen.	  Diffraction	  images	  were	  collected	  at	  NSLS	  X6A	  beamline,	  and	  
processed	  on-­‐site	  using	  HKL2000.31	  Phases	  were	  solved	  using	  a	  Fourier	  synthesis	  and	  
maps	  interpreted	  using	  Coot.9	  
	   The	  50mM	  soak	  was	  the	  only	  concentration	  in	  which	  there	  was	  a	  positive	  peak	  of	  
density	  in	  the	  Fo-­‐Fc	  map	  (Figure	  9).	  Building	  in	  the	  chaperone	  into	  the	  peak	  yielded	  a	  
	  23	  
fully	  occupied	  active	  site.	  We	  performed	  calculations	  that	  helped	  us	  to	  understand	  the	  
stoichiometry	  at	  equilibrium	  in	  conditions	  containing	  different	  [DGJ].	  
Calculations	  for	  Protein	  Concentration	  in	  a	  Crystal:	  
Number	  of	  Monomers	  Per	  Unit	  Cell	  =	  2	  Monomers	  /	  Asymmetric	  Unit	  •	  6	  Asymmetric	  
Units	  /	  Unit	  Cell	  =	  12	  Monomers	  per	  Unit	  Cell	  
Volume	  of	  a	  Unit	  Cell=	  100Å	  •	  100Å	  •	  200Å	  =	  0.1µm	  •	  0.1µm	  •	  0.2µm	  =	  .000002	  µm3	  /	  
Unit	  Cell	  
Volume	  of	  1	  Monomer	  =	  0.000000167	  µm3	  /	  monomer	  
Volume	  of	  a	  Crystal:	  100µm	  •	  100µm	  •	  100µm	  =	  106	  µm3	  /	  crystal	  
Number	  of	  Monomers	  per	  Crystal	  =	  (106	  µm3	  /	  crystal)	  /	  0.000000167	  µm3	  /	  monomer	  =	  
6	  •	  1012	  Monomers	  /	  Crystal	  
Concentration	  of	  Active	  Sites	  =	  6	  •	  1012	  Monomers	  /	  Crystal	  /	  6.02	  •	  1023	  =	  10-­‐11	  moles	  
Moles	  of	  Active	  Site	  to	  Liters	  =	  10-­‐11	  moles	  /	  10-­‐9	  L	  =	  0.1M	  =	  10mM	  of	  Active	  Sites	  
Calculations	  for	  Ligand	  Concentration	  in	  Soak	  Solution:	  
1mM	  Ligand	  in	  10µL	  
1mM	  /	  L	  •	  .00001L	  =	  0.000001	  mmoles	  •	  6.02	  •	  1020	  molecules	  /	  mmole	  =	  6.02	  •	  1015	  
molecules	  
10nM	  Ligand	  in	  10µL	  
10nM	  /	  L	  •	  .00001L	  =	  10-­‐11	  moles	  •	  6.02	  •	  1023	  molecules	  /	  moles	  =	  6.02	  •	  1012	  molecules	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At	  concentrations	  in	  the	  nanomolar	  range,	  there	  are	  roughly	  the	  same	  number	  
of	  ligand	  molecules	  as	  monomers.	  Every	  active	  site	  would	  have	  to	  bind	  to	  every	  
molecule	  in	  solution	  to	  obtain	  100%	  occupancy	  in	  the	  active	  site.	  At	  equilibrium	  there	  
are	  still	  molecules	  in	  solution,	  so	  full	  occupancy	  cannot	  be	  achieved.	  The	  issue	  in	  the	  
case	  is	  that	  we	  do	  not	  have	  enough	  molecules	  of	  ligand	  to	  saturate	  the	  enzyme	  under	  
equilbiruim	  conditions	  (Figure	  14).	  
For	  concentrations	  in	  the	  millimolar	  range,	  there	  are	  about	  1000	  ligand	  
molecules	  for	  every	  monomeric	  active	  site.	  This	  suggests	  that	  there	  are	  enough	  
molecules	  of	  ligand	  to	  observe	  a	  fully	  occupied	  active	  site	  in	  the	  electron	  density	  map.	  
The	  viscous	  nature	  of	  the	  cryoprotectant	  most	  likely	  prevented	  equilibrium	  from	  
occurring	  in	  the	  5	  minutes	  before	  freezing.	  Instead,	  we	  conclude	  that	  the	  ligand	  was	  
locally	  depleted	  around	  the	  crystal	  (Figure	  15).	  
3.6.	  Superimposition	  of	  Ligand	  Bound	  α-­‐GAL	  Structures	  
	   With	  a	  number	  of	  structures	  solved	  for	  both	  the	  Wild	  Type	  and	  D170A	  proteins,	  
a	  superimposition	  was	  made	  in	  order	  to	  visualize	  the	  mechanism	  of	  binding	  between	  
DGJ	  versus	  the	  natural	  substrate	  and	  product.	  The	  active	  site	  residues	  of	  each	  of	  the	  
structures	  were	  aligned	  using	  PyMol.32	  
	   The	  superimposition	  contains	  two	  wild	  type	  structures,	  one	  solved	  with	  DGJ	  and	  
one	  with	  galactose.	  The	  superimposition	  shows	  that	  DGJ	  not	  only	  binds	  in	  the	  same	  
orientation	  as	  the	  natural	  product,	  galactose,	  but	  also	  uses	  many	  of	  same	  active	  site	  
features	  to	  achieve	  its	  specificity.	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Compared	  to	  DGJ,	  galactose	  has	  one	  additional	  hydroxyl	  moiety,	  which	  it	  uses	  to	  
form	  an	  additional	  hydrogen	  bond	  to	  aspartic	  acid	  231.	  Whether	  or	  not	  this	  particular	  
hydrogen	  bond	  is	  present,	  the	  ligand	  binds	  in	  nearly	  the	  same	  conformation.	  This	  
suggests	  this	  bond	  is	  not	  significant	  for	  steering	  the	  ligand	  into	  the	  active	  site.	  However	  
when	  the	  salt	  bridge	  between	  the	  ligand	  and	  D170	  is	  abrogated,	  a	  shift	  in	  ligand	  binding	  
is	  seen.	  
	   There	  are	  currently	  structures	  for	  the	  α-­‐gal	  mutant	  D170A	  complexed	  
with	  melibiose	  and	  DGJ.	  Melibiose	  is	  a	  disaccharide	  of	  galactose	  and	  glucose	  that	  
contains	  an	  α-­‐linkage.	  Upon	  ligand	  binding	  to	  D170A,	  we	  see	  a	  shift	  of	  0.3	  Å	  by	  both	  DGJ	  
and	  melibiose	  as	  they	  move	  closer	  to	  the	  smaller	  alanine	  (Figure	  16).	  The	  steric	  strain	  
caused	  by	  the	  disaccharide	  causes	  the	  ring	  to	  shift	  laterally	  but	  does	  change	  the	  location	  
of	  the	  heterocyclic	  oxygen	  atom	  of	  the	  galactose	  relative	  to	  the	  amine	  nitrogen.	  Because	  
this	  shift	  is	  seen	  with	  in	  both	  pyranose	  and	  pyradine	  rings	  relative	  to	  the	  wild	  type	  
enzyme,	  this	  bond	  is	  clearly	  important	  to	  the	  binding.	  
3.7.	  Discussion	  
	   The	  structure	  without	  DGJ	  bound	  reveals	  the	  cryoprotectant	  glycerol	  occupying	  
the	  active	  site.	  At	  100mM	  DGJ,	  the	  active	  site	  is	  occupied	  by	  DGJ	  (Figure	  13).	  These	  two	  
end	  points	  were	  used	  to	  determine	  the	  two	  states	  of	  the	  enzyme	  and	  refine	  the	  final	  
positions	  of	  each	  ligand.	  At	  a	  concentration	  of	  0.1mM	  the	  active	  site	  contains	  only	  
glycerol.	  At	  the	  concentration	  of	  10mM,	  the	  2Fo-­‐Fc	  map	  shows	  density	  that	  resembles	  
an	  ensemble	  of	  DGJ	  and	  glycerol	  bound	  structures.	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The	  maps	  containing	  the	  ensemble	  were	  iteratively	  refined	  with	  different	  
fractional	  occupancies	  for	  the	  two	  ligands.	  We	  made	  a	  number	  of	  assumptions	  in	  order	  
to	  utilize	  the	  two-­‐state	  model.	  First,	  that	  the	  enzyme	  only	  exists	  in	  only	  two	  states,	  
either	  glycerol	  bound,	  or	  DGJ	  bound.	  It	  is	  also	  assumed	  that	  the	  ligand	  concentration	  
stays	  constant	  throughout	  the	  course	  of	  the	  experiment.	  Finally,	  the	  model	  dictates	  that	  
the	  binding	  equilibrium	  of	  the	  protein	  in	  crystal	  form	  is	  identical	  to	  that	  of	  protein	  in	  
free	  solution.	  
The	  occupancies	  of	  each	  ligand	  were	  refined	  in	  10%	  increments	  against	  the	  
10mM	  data	  set	  so	  that,	  
OccupancyGlycerol(ON)+OccupancyDGJ(OL)	  =	  1.0	  
This	  iteration	  resulted	  in	  eleven	  data	  sets	  which	  ranged	  from	  100%	  Glycerol	  and	  
0%	  DGJ	  to	  0%	  Glycerol	  and	  100%	  DGJ.	  At	  100%	  Glycerol	  there	  is	  a	  strong	  positive	  peak	  in	  
the	  Fo-­‐Fc	  map.	  At	  100%	  DGJ,	  we	  see	  a	  strong	  negative	  peak	  in	  the	  Fo-­‐Fc.	  Out	  of	  the	  
other	  combinations	  of	  partial	  occupancies,	  only	  one	  does	  not	  have	  either	  a	  positive	  or	  
negative	  peak	  in	  the	  Fo-­‐Fc	  map.	  	  
	  	   The	  combination	  of	  70%	  Glycerol	  and	  30%	  DGJ	  results	  in	  a	  map	  without	  
any	  significant	  peaks	  in	  the	  difference	  map.	  Fractional	  occupancy	  relates	  to	  the	  crystal	  
dissociation	  constant	  (KCD)	  in	  the	  following	  way:
42	  
KD	  	  =	  KCD	  =	  [P]•[L]/[PL]	  
[PL]=[P]Total•OL	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[P]=[P]Total(1-­‐OL)	  
KCD	  =	  {[P]Total(1-­‐OL)}[L]	  /	  {[P]Total•OL}	  
KCD	  =	  (1-­‐OL)[L]/OL	  
OL/ON=[L]/KCD	  
0.3/0.7=[10mM]/KCD,	  KCD	  =	  23.3	  mM	  
	   Abby	  Guce’s	  pulse	  proteolysis	  experiments	  demonstrate	  that	  when	  the	  salt	  
bridge	  is	  disrupted	  in	  the	  D170	  mutant,	  DGJ	  protects	  no	  better	  than	  galactose	  against	  
digestion	  (Guce,submitted).	  The	  KI	  for	  galactose	  in	  the	  Wild	  Type	  enzyme	  is	  16mM,	  so	  
we	  would	  expect	  something	  similar	  for	  our	  KCD.	  
	   This	  dissociation	  constant	  could	  be	  further	  refined	  by	  utilizing	  the	  SHELX	  suite	  of	  
programs	  to	  refine	  the	  partial	  occupancies	  of	  both	  ligands	  in	  the	  structure.	  The	  
dissociation	  constant	  reached	  by	  our	  crystallographic	  trials	  may	  also	  be	  slightly	  higher	  
than	  the	  true	  KD	  due	  to	  the	  effect	  of	  glycerol	  in	  the	  active	  site.	  It	  may	  take	  a	  slightly	  
higher	  concentration	  of	  DGJ	  to	  out	  compete	  glycerol	  for	  the	  active	  site.	  This	  would	  drive	  
the	  KD	  higher	  than	  if	  just	  water	  molecules	  occupied	  the	  active	  site.	  
	   This	  method	  of	  determining	  dissociation	  constant	  through	  x-­‐ray	  crystallography	  
can	  be	  practical	  with	  proteins	  in	  which	  traditional	  functional	  and	  activity-­‐based	  assays	  
are	  not	  an	  option.	  With	  the	  advent	  of	  high-­‐intensity	  synchrotron	  x-­‐ray	  sources,	  fast	  CCD	  
detectors,	  remote	  collection,	  and	  the	  increased	  processing	  power	  of	  personal	  
computers,	  diffraction	  experiments	  can	  be	  run	  more	  efficiently	  than	  ever.	  This	  thesis	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has	  utilized	  many	  of	  these	  technologies	  and	  demonstrated	  the	  ability	  of	  the	  two	  state	  
model	  to	  successfully	  determine	  a	  dissociation	  constant.	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   CHAPTER	  4	  
	  
MATERIALS	  AND	  METHODS	  
4.1.	  Bacterial	  Transformation	  with	  pIB-­‐V5-­‐His-­‐TOPO-­‐α-­‐GAL	  
	   A	  previously	  purified	  stock	  of	  pIB-­‐V5-­‐His-­‐TOPO-­‐α-­‐GAL	  was	  used	  to	  transform	  
competent	  DH-­‐5α	  cells.	  After	  being	  thawed	  on	  ice,	  cells	  were	  heat	  shocked	  for	  45	  
seconds	  in	  a	  water	  bath	  at	  42°	  C	  in	  the	  presence	  of	  50ng	  of	  plasmid.	  Then	  the	  cells	  were	  
then	  spread	  onto	  agar	  plates	  containing	  ampicillin.	  
	   The	  plates	  were	  incubated	  at	  37°	  C	  overnight.	  All	  of	  the	  plates	  yielded	  colonies	  
and	  small	  isolated	  colonies	  were	  re-­‐streaked	  on	  ampicillin	  plates	  to	  ensure	  resistance.	  
Under	  sterile	  conditions,	  another	  single	  colony	  was	  selected	  with	  a	  pipette	  tip	  and	  
placed	  into	  a	  10mL	  culture	  tube	  containing	  5mL	  of	  LB	  growth	  media	  containing	  
tryptone,	  yeast	  extract,	  so2dium	  chloride	  and	  ampicillin.	  Cultures	  were	  grown	  at	  37°	  C	  
overnight	  and	  the	  plasmid	  isolated	  the	  following	  day.	  
4.2.	  DNA	  Isolation	  and	  Purification	  
	   In	  order	  to	  isolate	  our	  plasmid	  of	  interest,	  1000uL	  of	  bacterial	  culture	  was	  added	  
to	  a	  1.5mL	  centrifuge	  tube	  and	  spun	  at	  maximum	  speed	  in	  a	  centrifuge	  for	  30	  seconds	  
and	  supernatant	  was	  collected.	  Another	  1000uL	  of	  bacterial	  culture	  was	  added	  to	  the	  
same	  tube,	  and	  spun	  down	  for	  another	  30	  seconds.	  The	  resulting	  pellet	  was	  
resuspended	  and	  100uL	  of	  lysis	  buffer	  was	  added.	  After	  90	  seconds,	  lysis	  neutralization	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solution	  containing	  20%	  guanidinium	  chloride	  was	  added	  and	  the	  lysate	  centrifuged	  for	  
3	  minutes.	  The	  supernatant	  was	  applied	  to	  a	  Promega	  Pure	  Yield	  Collection	  Tube.	  The	  
supernatant	  was	  passed	  through	  the	  column	  after	  15	  seconds	  of	  centrifugation	  and	  the	  
flow	  through	  discarded.	  The	  column	  was	  then	  washed	  and	  transferred	  to	  a	  clean	  1.5ml	  
tube.	  DNA	  was	  eluted	  in	  30uL	  of	  TE	  buffer	  that	  was	  warmed	  to	  47	  degrees	  C°	  in	  a	  water	  
bath.	  
4.3.	  DNA	  Sequencing	  
	  	   The	  resulting	  plasmid	  was	  mixed	  in	  a	  PCR	  strip.	  Reactions	  contained	  10ul	  of	  DNA	  
plasmid	  along	  with	  5uL	  of	  either	  the	  OpIE2	  forward	  or	  reverse	  primer.	  This	  primer	  flanks	  
the	  multiple	  cloning	  site,	  where	  the	  GLA	  gene	  was	  inserted.	  	  Sequencing	  data	  returned	  
from	  Genewiz	  Incorporated	  confirmed	  our	  plasmid	  was	  indeed	  wild-­‐type.	  	  
4.4.	  Insect	  Cell	  Transfection	  
	  	   The	  plasmid	  construct	  was	  transfected	  into	  Invitrogen	  High-­‐Five	  insect	  cells,	  
which	  are	  eukaryotic	  cells	  that	  are	  able	  to	  propagate	  in	  serum-­‐free	  culture.	  The	  cells	  are	  
derived	  from	  the	  Trichoplusia	  ni	  organism	  and	  are	  typically	  used	  as	  an	  expression	  
system	  for	  Baculovirus	  expression	  vectors.	  Tn5	  cells	  were	  cultured	  in	  a	  suspension	  flask	  
containing	  15mL	  Hyclone-­‐SFX	  media	  until	  they	  reached	  a	  density	  of	  2.0	  x	  106	  and	  
viability	  greater	  than	  95%.	  	  
	   From	  this	  suspension	  flask	  a	  T-­‐25	  flask	  was	  seeded	  with	  3.6	  x	  106	  cells	  and	  media	  
was	  added	  to	  a	  final	  volume	  of	  5mL.	  The	  cells	  were	  given	  ample	  time	  to	  adhere	  to	  the	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flask.	  The	  media	  was	  replaced	  with	  a	  transfection	  mixture	  containing	  1.8ug	  of	  DNA	  and	  
36.4	  µL	  of	  Cellfectin	  transfection	  reagent	  (Invitrogen)	  after	  the	  mixture	  had	  been	  
allowed	  to	  incubate	  for	  15	  minutes.	  This	  allows	  the	  liposomes	  to	  form.	  The	  cells	  were	  
rocked	  at	  2	  rocks	  per	  minute	  for	  4	  hours.	  Then	  4	  mL	  of	  SFX	  was	  added	  to	  the	  culture	  and	  
incubated	  at	  37°	  C.	  After	  two	  days,	  the	  media	  and	  transfection	  mixture	  was	  replaced	  
with	  media	  containing	  100	  µg/mL	  of	  blasticidin	  to	  select	  for	  integrated	  DNA.	  The	  media	  
was	  replaced	  every	  two	  days	  for	  10	  days	  until	  the	  culture	  became	  confluent.	  The	  cells	  
were	  gently	  suspended	  into	  the	  media	  using	  a	  pipette	  and	  transferred	  to	  a	  suspension	  
culture	  containing	  10	  µg/mL	  blasticidin.	  
4.5.	  Large	  Scale	  Expression	  and	  Purification	  
	  	   Freezer	  stocks	  from	  previously	  made	  stable	  cell	  lines	  were	  recovered	  in	  SFX	  
media.	  Cells	  were	  stained	  and	  counted	  using	  Trypan	  Blue	  to	  monitor	  viability	  and	  
density.	  The	  starter	  culture	  was	  scaled	  up	  to	  approximately	  500mL	  of	  suspension	  culture	  
in	  homemade	  ISFM	  media.	  This	  serum-­‐free	  media	  was	  optimized	  for	  the	  culture	  of	  
insect	  cells	  and	  contains	  a	  yeastolate	  base	  with	  a	  lipid-­‐ethanol	  emulsion	  and	  Pluronic	  to	  
protect	  against	  sheer	  forces.24	  Once	  it	  reached	  a	  density	  of	  2	  x	  106	  cells	  per	  mL.	  it	  was	  
split	  into	  four	  1L	  fernbach	  flasks	  with	  ISFM	  media.	  The	  culture	  was	  allowed	  to	  shake	  at	  
37°	  C	  for	  three	  days.	  Our	  protein	  of	  interest	  is	  translated	  with	  a	  secretion	  sequence	  that	  
allowed	  the	  protein	  to	  be	  harvested	  directly	  from	  the	  supernatant.	  	  
	   The	  supernatant	  was	  collected	  and	  centrifuged	  to	  remove	  cells	  and	  debris.	  The	  
clarified	  media	  had	  0.01%	  Sodium	  Azide	  (NaN3)	  was	  added	  to	  the	  supernatant	  a	  final	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concentration	  of	  0.01%	  to	  inhibit	  bacterial	  and	  fungal	  growth	  and	  stored	  at	  4°	  C.	  The	  
supernatant	  was	  then	  concentrated	  and	  buffer	  exchanged	  into	  Nickel	  Wash	  Buffer	  
(20mM	  Imidazole,	  500mM	  Sodium	  Chloride,	  10mM	  Sodium	  Phosphate,	  pH	  7.5)	  using	  a	  
preparative	  scale	  tangential	  flow	  cartridge	  from	  Millipore.	  The	  Ni-­‐Wash	  buffer	  contained	  
20mM	  imidazole	  to	  prevent	  non-­‐specific	  binding	  to	  the	  5mL	  Pre-­‐packed	  Nickel	  Column.	  
	  	  	   The	  200mL	  of	  retentate	  was	  loaded	  onto	  a	  5mL	  pre-­‐packed	  Ni-­‐Sepharose	  column	  
at	  1mL/min	  using	  a	  Bio-­‐Rad	  Biologic	  Duo-­‐Flow	  FPLC.	  The	  hexahistidine-­‐tagged	  α-­‐
galactosidase	  was	  eluted	  from	  the	  Nickel	  column	  using	  10mM	  phosphate	  buffer	  
containing	  400mM	  imidazole.	  The	  column	  was	  washed	  until	  the	  UV	  absorbance	  reached	  
baseline	  and	  then	  the	  protein	  was	  eluted	  using	  a	  gradient	  of	  imidazole	  from	  20mM	  to	  
160mM	  over	  200mL.	  Fractions	  were	  collected	  every	  1.5	  mL.	  Fractions	  were	  tested	  using	  
a	  X-­‐α-­‐gal	  substrate	  to	  assay	  for	  activity.	  This	  substrate	  contains	  a	  chromophore	  α-­‐linked	  
to	  a	  galactose.	  Upon	  cleavage	  by	  α-­‐gal,	  the	  chromophore	  is	  activated.	  In	  order	  to	  test	  
for	  activity,	  X-­‐α-­‐gal	  was	  dissolved	  in	  dimethylformamide	  solvent	  and	  diluted	  in	  TBS	  to	  a	  
final	  concentration	  of	  0.1mg/mL.	  Fractions	  were	  dot-­‐blotted	  using	  a	  vacuum	  manifold	  
onto	  a	  PVDF	  membrane	  and	  incubated	  overnight	  at	  37°	  C.	  The	  positive	  fractions	  were	  
loaded	  on	  a	  reducing	  SDS-­‐PAGE	  gel	  and	  stained	  using	  GelCode	  Blue	  from	  Pierce.	  The	  
SDS-­‐PAGE	  gel	  showed	  a	  band	  between	  the	  43	  kDa	  and	  56	  kDa	  markers.	  Insect-­‐expressed	  
human	  α-­‐gal	  typically	  runs	  at	  about	  47	  kDa	  on	  a	  reducing	  gel.	  Fractions	  that	  were	  
judged	  to	  be	  pure	  were	  pooled	  and	  concentrated	  to	  7	  mg/mL.	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4.6.	  WT	  Crystal	  Trays	  
Purified	  human	  α-­‐gal	  from	  4L	  of	  insect	  cell	  culture	  was	  placed	  into	  known	  conditions	  
that	  yielded	  P212121	  crystals	  (12%	  PEG	  8K,	  22mM	  Magnesium	  Acetate,	  100mM	  Sodium	  
Cacodylate	  pH	  6.5).	  Hanging	  drop	  trials	  were	  set	  up	  around	  12%	  PEG	  without	  substantial	  
crystals.	  Following	  trays	  varied	  concentrations	  of	  polyethylene	  glycol,	  Magnesium	  
Acetate,	  the	  ratio	  of	  protein	  to	  mother	  liquor	  and	  initial	  concentration	  of	  protein.	  Micro	  
crystals	  were	  obtained	  but	  none	  were	  of	  sufficient	  quality	  to	  be	  used	  in	  x-­‐ray	  diffraction	  
experiments.	  
4.7.	  2nd	  Binding	  and	  Chaperone	  Titration	  Soak	  
	   Crystals	  were	  harvested	  from	  the	  hanging	  drop	  using	  a	  Hampton	  Cryo-­‐loop	  and	  
deposited	  in	  crystallization	  buffer	  with	  30%	  PEG	  4K.	  Crystals	  were	  moved	  into	  increasing	  
concentrations	  of	  glycerol	  until	  a	  final	  concentration	  of	  20%	  was	  reached.	  At	  this	  point	  9	  
µL	  of	  buffer	  including	  the	  crystal	  was	  pipetted	  to	  a	  cover	  slip.	  Either	  1µL	  of	  Silver	  Bullet	  
solution	  or	  1µL	  of	  pharmacological	  chaperone	  was	  added	  to	  the	  crystal.	  The	  solution	  
was	  pipetted	  gently	  to	  ensure	  equilibration.	  	  The	  crystal	  was	  then	  frozen	  in	  liquid	  
nitrogen	  and	  directly	  mounted	  on	  the	  generator	  or	  stored	  for	  future	  collection	  at	  the	  
synchrotron.	  	  
4.8.	  Data	  Collection	  and	  Integration	  
	  	   Initial	  collections	  occurred	  on	  the	  in-­‐house	  rotating	  anode	  x-­‐ray	  generator	  
(Rigaku)	  paired	  with	  a	  R-­‐Axis	  IV++	  detector.	  Crystals	  that	  had	  been	  soaked	  in	  ligand	  
required	  15	  minutes	  of	  exposure	  per	  degree	  of	  rotation.	  	  The	  crystal	  was	  rotated	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through	  at	  least	  60	  degrees	  to	  ensure	  a	  complete	  collection	  with	  sufficient	  redundancy.	  
The	  frozen	  crystal	  was	  maintained	  by	  a	  cryostream	  that	  provided	  10L/min	  of	  liquid	  
nitrogen	  per	  min	  and	  8L/min	  of	  shield	  flow.	  Diffraction	  patterns	  were	  recorded	  for	  every	  
degree	  of	  rotation.	  
	   Crystals	  collected	  at	  the	  X6A	  beam	  line	  at	  the	  NSLS	  were	  collected	  between	  five	  
and	  thirty	  -­‐second	  exposures	  and	  in	  half-­‐degree	  rotations.	  	  
	   The	  images	  were	  read	  and	  integrated	  using	  HKL2000.31	  After	  an	  initial	  peak	  
search	  was	  performed,	  the	  crystal	  was	  indexed	  in	  the	  P3221	  space	  group.	  This	  space	  
group	  gave	  unit	  cell	  constants	  of	  about	  (90Å,	  90Å,	  216Å)	  and	  angles	  of	  (90°,	  90°,	  120°).	  
The	  diffraction	  images	  were	  then	  integrated	  and	  scaled	  and	  the	  scale.log	  file	  checked	  for	  
R-­‐factor	  and	  completeness.	  The	  resolution	  of	  the	  data	  was	  cut	  at	  an	  average	  I/σ	  in	  the	  
highest	  resolution	  shell	  of	  about	  2.0.	  
4.9.Fourier	  Synthesis	  for	  Phase	  Calculation	  
	  	   After	  the	  data	  were	  scaled	  in	  the	  final	  P3221	  	  space	  group,	  the	  reflection	  data	  
exist	  as	  a	  series	  of	  intensities,	  one	  for	  each	  integrated	  reflection.	  	   In	  order	  to	  solve	  the	  
phase	  problem,	  we	  used	  the	  Fourier	  synthesis	  method.	  This	  method	  takes	  a	  previously	  
elucidated	  model,	  generates	  calculated	  phases	  for	  the	  structure	  factors	  from	  the	  model	  
and	  uses	  them	  to	  render	  a	  map	  using	  the	  new	  observed	  data.	  These	  complete	  data	  are	  
stored	  in	  file	  with	  the	  extension	  *.mtz.	  The	  data	  file	  contain	  the	  reflections	  index	  (h,k,l),	  
and	  the	  free	  set	  of	  reflections	  not	  used	  for	  refinement.	  Additionally,	  it	  contains	  the	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observed	  structure	  factors	  and	  their	  errors	  	  (Fobs,	  SigFObs),	  and	  the	  calculated	  structure	  
factors	  from	  the	  model	  (Fcalc,	  PHICalc).	  	  
	  	   To	  calculate	  FCalc	  and	  PHICalc	  from	  an	  observed	  model,	  3HG2	  was	  downloaded	  
from	  the	  PDB.	  Using	  a	  text	  editor	  all	  of	  the	  ligands,	  including	  glycans,	  and	  waters,	  were	  
removed	  from	  the	  model.	  The	  CCP4	  program	  “SFALL”	  was	  then	  used	  to	  generate	  FCalc	  
and	  PHICalc	  from	  the	  reduced	  model.	  Once	  the	  structure	  factors	  and	  phases	  are	  
calculated	  from	  the	  model,	  the	  experimental	  data	  integrated,	  scaled,	  and	  merged	  with	  
the	  model	  data.	  
	  	   The	  HKL2000	  graphical	  user	  interface	  was	  used	  to	  integrate	  and	  scale	  the	  data	  as	  
mentioned	  previously34.	  The	  output	  file	  (*.sca)	  was	  converted	  into	  a	  (.mtz)	  containing	  
aforementioned	  intensities	  (I)	  and	  the	  error	  of	  the	  intensities	  (SigI).	  “Truncate”	  is	  the	  
CCP4	  program	  that	  was	  used	  to	  convert	  these	  intensitites	  into	  the	  structure	  factors	  
(Fobs,	  SigFObs).	  
	   The	  structure	  factors	  from	  the	  model	  can	  be	  merged	  with	  the	  structure	  factors	  
from	  the	  integrated	  and	  scaled	  data	  using	  “CAD”.	  A	  map	  is	  now	  able	  to	  be	  rendered,	  and	  
correct	  indeces	  chosen.	  After	  the	  Fobs	  and	  FCalc	  set	  to	  the	  same	  indexing	  convention,	  a	  
map	  can	  be	  calculated.	  There	  are	  two	  arbitrary	  choices	  for	  indexing	  data	  in	  P3221,	  so	  we	  
checked	  each	  new	  data	  set	  to	  ensure	  that	  it	  matched	  the	  previous	  convention.	  
	   In	  order	  to	  determine	  if	  the	  structure	  factors	  are	  on	  the	  same	  indices,	  a	  R-­‐factor	  
can	  be	  calculated	  between	  the	  two	  sets	  of	  Fobs	  reflections.	  “Sf	  Analyze”	  was	  used	  to	  
generate	  this	  factor	  along	  with	  the	  correlation.	  The	  reflections	  were	  then	  reindexed	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using	  the	  transformation	  (-­‐h,-­‐k,l)	  and	  the	  R-­‐factor	  was	  recalculated.	  The	  set	  with	  the	  
lower	  R-­‐factor	  and	  higher	  correlation	  was	  determined	  to	  be	  correctly	  indexed.	  If	  
reinexing	  was	  necessary,	  the	  data	  was	  remerged	  with	  “CAD”	  before	  refinement	  was	  
carried	  out.	  
4.10.	  Refinement	  Using	  REFMAC5	  
	   Refinement	  was	  carried	  out	  using	  “REFMAC5”	  which	  is	  distributed	  with	  the	  CCP4	  
suite.5	  Once	  a	  complete	  (*.mtz)	  file	  was	  created	  and	  a	  starting	  model	  (modified	  
PDB:3HG2)	  was	  obtained,	  the	  model	  was	  rigid	  body	  refined	  against	  the	  experimental	  
data.	  	  
After	  rigid	  body	  was	  complete,	  the	  output	  (*.pdb)	  and	  (*.mtz)	  was	  loaded	  into	  
“Coot”.9	  “Coot”	  has	  the	  ability	  to	  render	  weighted	  2Fo-­‐Fc	  and	  Fo-­‐Fc	  maps	  directly	  from	  
the	  (*.mtz)	  file.	  Phases	  were	  determined	  sufficient	  if	  there	  were	  significant	  peaks	  in	  the	  
Sigma-­‐A	  weighted	  difference	  map	  (m|Fo|	  -­‐	  D|Fc|)	  exp(i	  PhiCalc)	  for	  the	  removed	  
ligands	  and	  glycans.8	  
	   Restrained	  refinement	  was	  then	  used	  to	  refine	  side	  chain	  and	  backbone	  
variances	  from	  the	  starting	  model.	  Iterative	  cycles	  of	  restrained	  refinement	  and	  model	  
building	  were	  used	  until	  acceptable	  R-­‐factors	  were	  reached.	  Ligands	  were	  added	  from	  
the	  “REFMAC5”	  dictionary	  and	  custom	  dictionaries.33	  TLS	  and	  NCS	  restraints	  were	  
applied	  on	  two	  domains	  of	  each	  monomer.	  Automatic	  weighting	  was	  turned	  off,	  instead	  
a	  weighting	  term	  of	  0.05	  was	  found	  to	  be	  sufficient.	  The	  default	  B-­‐factor	  restraints	  were	  
	  37	  
also	  loosened	  for	  the	  main	  and	  side	  chain	  bonds	  and	  angles.	  The	  omit	  maps	  for	  
pharmacological	  chaperone	  were	  calculated	  using	  “SFCheck"	  and	  the	  final	  models	  were	  
rendered	  and	  superimposed	  in	  PyMol.32	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Figure	  1	  –	  Human	  α-­‐Galactosidase.	  The	  structure	  of	  human	  α-­‐galactosidase	  with	  the	  
pharmacological	  chaperone	  DGJ	  bound	  at	  both	  active	  sites.
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Figure	  2	  –	  1-­‐deoxygalactonojirimycin	  and	  galactose.The	  structure	  of	  the	  amino-­‐sugar	  DGJ	  that	  has	  the	  ability	  to	  serve	  as	  a	  
pharmacological	  chaperone	  at	  sub-­‐nanomolar	  concentrations.	  Galactose	  provides	  some	  chaperoning	  activity	  but	  lacks	  the	  secondary	  
amine	  that	  provides	  the	  high	  affinity	  DGJ	  has	  for	  the	  enzyme.
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Figure	  3	  –	  Active	  Site	  of	  Human	  α-­‐galactosidase.
	  42	  
	  
	  
Figure	  4	  –	  WT	  Crystals	  –	  Effect	  of	  Protein:Buffer	  Ratio.	  A.	  Fabrazyme	  crystallized	  at	  with	  twice	  as	  much	  crystallization	  buffer	  as	  
protein,	  B.	  Fabrazyme	  crystallized	  the	  same	  amount	  of	  crystallization	  buffer	  as	  protein,	  C.	  Fabrazyme	  crystallized	  at	  with	  half	  as	  
much	  crystallization	  buffer	  as	  protein.
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Figure	  5	  –	  The	  Second	  Binding	  Site	  of	  human	  α-­‐gal.	  A	  stick	  representation	  of	  the	  carbohydrate-­‐binding	  site	  reported	  by	  Guce	  et	  al.	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Figure	  6	  –	  SiteHound	  Calculated	  Binding	  Site.	  The	  result	  of	  the	  SiteHound	  binding	  program	  on	  human	  α-­‐gal	  bound	  with	  product	  
(3HG5).	  The	  blue	  spheres	  represent	  the	  low-­‐scoring	  patch	  around	  Y329.	  The	  dark	  blue	  patch	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Figure	  7	  –	  Space	  Group	  Issues.	  The	  P3221	  space	  group	  packs	  the	  dimers	  in	  a	  way	  that	  occludes	  ligand	  from	  binding	  to	  the	  B-­‐copy	  
second	  site	  Y329	  (magenta).	  The	  A-­‐copy	  (yellow)	  is	  still	  available	  to	  bind	  ligand.
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Figure	  8	  –	  Secondary	  Site	  Soak	  Results.	  A.	  3HG2	  Trimmed	  to	  3.2	  Å,	  B.	  Silver	  Bullet	  A2,	  C.	  
Silver	  Bullet	  A3,	  D.	  Silver	  Bullet	  A4-­‐A8,	  E.	  100mM	  Phenol,	  F.	  100mM	  Cyclohexanol,	  G.	  
Silver	  Bullet	  E4	  F.	  Silver	  Bullet	  F2.	  The	  minor	  peak	  in	  the	  Fo-­‐Fc	  map	  represents	  ethylene	  
glycol	  bound	  to	  the	  second	  site.
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Figure	  9	  –	  Fabrazyme	  soaked	  with	  50mM	  1-­‐deoxygalactonojirimycin.	  A	  calculated	  omit	  map	  contoured	  at	  1	  Sigma	  around	  the	  
ligand	  of	  interest
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Figure	  10	  –	  D170A	  Crystals	  –	  Effect	  of	  PEG	  4K	  Concentration.	  The	  largest	  crystals	  
formed	  at	  the	  lowest	  concentration	  of	  PEG.	  A.	  to	  D.	  represent	  a	  gradient	  of	  PEG4K	  from	  
15-­‐22.5%.	  
Figure	  11	  –	  The	  Two	  States	  of	  the	  Active	  Site	  During	  DGJ	  Titration.	  A.	  The	  active	  site	  of	  
α-­‐gal	  with	  0mM	  DGJ,	  where	  a	  glycerol	  molecule	  is	  present.	  B.	  The	  active	  site	  fully	  
occupied	  at	  100mM	  DGJ.	  Both	  maps	  are	  2Fo-­‐Fc	  contoured	  at	  1	  Sigma.	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Figure	  12	  –	  D170A	  Soaked	  with	  10mM	  1-­‐deoxygalactonojirimycin.	  A	  through	  K	  Two	  
State	  Model	  Refined	  with	  varying	  occupancies.	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Figure	  13	  –	  D170A	  soaked	  with	  100mM	  1-­‐deoxygalactonojirimycin.	  A	  calculated	  omit	  map	  contoured	  at	  1	  Sigma	  around	  the	  active-­‐
site	  ligand	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Figure	  14	  –	  Diagram	  of	  Ligand	  Depletion	  During	  Wild	  Type	  Crystal	  Soaks	  at	  Low	  [DGJ].	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Figure	  15	  –	  Diagram	  of	  Incomplete	  Equilibration	  During	  Wild	  Type	  Crystal	  Soaks	  at	  High	  [DGJ].	  
	  
	  53	  
Figure	  16	  –	  Superimposition	  of	  Known	  D170A	  and	  WT	  structures.	  Four	  structures	  were	  
superimposed	  using	  PyMol.	  The	  D170A	  structures	  are	  colored	  in	  shades	  of	  yellow	  and	  
the	  two	  ligands	  are	  DGJ	  and	  melibiose.	  The	  WT	  structures	  are	  colored	  in	  shades	  of	  blue	  
and	  contain	  the	  ligands	  of	  DGJ	  and	  Galactose.	  The	  removal	  of	  the	  carboxylate	  from	  the	  
protein	  allows	  the	  ligand	  to	  shift	  0.3	  Å	  upward	  to	  fill	  the	  void.	  
D170A + Melibiose
D170A + DGJ
WT + Galactose
WT + DGJ
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APPENDIX	  A	  
	  
CRYSTALLOGRAPHIC	  TABLES	  
Table	  A.1:	  2nd	  Binding	  Soaks	  
 
Data Collection A1 Collection A2 Collection A3 Collection A4-A8 Soak Phenol 
Protein Fabrazyme Fabrazyme Fabrazyme Fabrazyme Fabrazyme 
Space Group P3
2
21 P3
2
21 P3
2
21 P3
2
21 P3
2
21 
Cell Constants, A° 90.65  90.65 216.79 89.87 89.87 216.06 90.29  90.29 215.93 90.61  90.61 216.24 90.73  90.73 217.17 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
      
X-Ray Source In-House In-House In-House In-House In-House 
Wavelength, A° 1.54 1.54 1.54 1.54 1.54 
Resolution (last shell) 50.00 - 2.66 50.00 - 3.17 50.00 - 2.73 50.00 - 2.68 50.00 - 2.50 
Unique Observations 30598 17856 27771 27247 31835 
Completeness, % (last 
shell) 99.9 (99.3) 99.5 (99.8) 99.4 (97.7) 91.6 (95.3) 86.4 (43.7) 
Multiplicity (last shell) 8.3 (8.1) 5.8 (5.8) 7.7 (7.1) 3.4 (3.1) 10.2 (6.7) 
R
sym 
(last shell) 17.3 (74.4) 22.9 (89.7) 16.8 (83.9) 10.2 (45.0) 9.9 (50.2) 
I/σ
I 
(last shell) 13.2 (2.66) 8.23 (1.94) 12.16 (2.00) 10.72 (2.05) 23.75 (2.56) 
      
R
work
/R
free
b% Rigid Body 25.8/27.2 27.7/27.9 25.7/26.9 24.7/26.2 25.6/26.9 
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Data Collection Cyclohexanol E4 Collection F2 Collection 
Product + Formic 
Acid 
Protein Fabrazyme Fabrazyme Fabrazyme D170A 
Space Group P3
2
21 P3
2
21 P3
2
21 P3
2
21 
Cell Constants, A° 90.35  90.35 216.80 90.51  90.51 217.26 90.69  90.69 217.15 89.56  89.56 215.53 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
     
X-Ray Source In-House NSLS - X6A NSLS - X6A In-House 
Wavelength, A° 1.54 0.97 0.97 1.54 
Resolution (last shell) 50.00 - 3.17 50.00 - 2.95 50.00 - 2.95 50.00 - 3.60 
Unique Observations 18118 22572 22579 11625 
Completeness, % (last 
shell) 99.9 (100.0) 99.9 (99.9) 99.9 (100.0) 95.0 (96.6) 
Multiplicity (last shell) 5.5 (5.6) 6.0 (6.2) 8.2 (8.0) 3.3 (3.3) 
R
sym 
(last shell) 20.5 (82.9) 16.4 (85.0) 21.4 (0.00) 22.9 (67.9) 
I/σ
I 
(last shell) 8.87 (2.00) 11.22 (2.07) 12.63 (1.93) 5.58 (2.03) 
     
R
work
/R
free
b% Rigid Body 26.5/26.7 25.4/26.6 24.8/25.4 31.9/32.4 
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Table	  A.2:	  Pharmacological	  Chaperone	  Titrations	  –	  D170A	  –	  Glycerol	  Cryoprotectant	  
 DGJ 0.0mM DGJ 0.1mM DGJ 1mM DGJ 10mM DGJ 100mM 
Data Collection      
Protein D170A D170A D170A D170A D170A 
Space Group P3
2
21 P3
2
21 P3
2
21 P3
2
21 P3
2
21 
Cell Constants, A° 90.61  90.61 216.64 90.31  90.31 216.16 90.37  90.37 216.44 90.18  90.18 216.20 90.467  90.47 216.54 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
X-Ray Source NSLS - X6A NSLS - X6A NSLS - X6A NSLS - X6A NSLS - X6A 
Wavelength, A° 0.97 0.97 0.97 0.97 0.97 
Resolution (last shell) 50.00 - 2.41 50.00 - 2.32 50.00 - 2.43 50.00 - 2.77 50.00 - 2.64 
Unique Observations 38039 45035 39340 26748 31099 
Completeness, % (last 
shell) 93.4 (95.8) 99.7 (99.4) 99.6 (99.4) 99.8 (100.0) 99.8 (99.8) 
Multiplicity (last shell) 6.3 (4.8) 5.4 (5.2) 6.1 (6.2) 7.3 (7.4) 5.8 (5.3) 
R
sym 
(last shell) 15.8 (74.3) 17.1 (0.00) 15.3 (82.5) 20.2 (96.3) 17.2 (68.5) 
I/σ
I 
(last shell) 11.8 (2.10) 14.7 (2.05) 12.4 (1.98) 10.8 (1.98) 10.6 (2.04) 
R
work
/R
free
b% Rigid Body 25.9/27.1 28.4/29.2 27.6/28.0 26.5/27.3 25.9/27.4 
Refinement      
Resolution (Å) 50.00 - 2.41 50.00 – 2.32 50.00 – 2.43 50.00 – 2.77 50.00 - 2.64 
No. reflections 38029 45109 39434 19152 29351 
Rwork / Rfree 17.1 / 21.6 19.9 / 23.7 19.1 / 23.0 16.5 / 22.9 19.2 / 24.3 
No. atoms 6604 6637 6659 6630 6723 
B-factors 11.6 15.4 17.3 29.9 30.1 
R.m.s. deviations      
    Bond lengths (Å) 0.008 .008 .008 .011 0.009 
    Bond angles (°) 1.128 1.167 1.149 1.401 1.216 
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Table	  A.3:	  Pharmacological	  Chaperone	  Titrations	  –	  Wild	  Type	  –	  Glycerol	  Cryoprotectant	  
 
Data Collection DGJ_0mM DGJ_10nM DGJ_100nM DGJ_1uM 
Protein Fabrazyme Fabrazyme Fabrazyme Fabrazyme 
Space Group P3
2
21 P3
2
21 P3
2
21 P3
2
21 
Cell Constants, A° 90.20 90.20 216.54 89.88  89.88 216.18 90.44  90.44 216.55 90.33  90.33 216.80 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
     
X-Ray Source NSLS - X6A NSLS - X6A NSLS - X6A NSLS - X6A 
Wavelength, A° 1.1 1.1 1.1 1.1 
Resolution (last shell) 50.0 - 2.0 50.00 - 2.15 50.00 - 1.95 50.0 - 1.8 
Unique Observations 69918 55740 75624 94468 
Completeness, % (last 
shell) 100.0 (100.0) 99.9 (100.0) 99.9 (99.9) 98.5 (99.3) 
Multiplicity (last shell) 11.0 (11.0) 5.5 (5.5) 10.9 (10.4) 10.8 (11.0) 
R
sym 
(last shell) 10.3 (0.0) 8.9 (64.0) 9.1 (91.0) 8.8 (0.0) 
I/σ
I 
(last shell) 26.4 (2.13) 22.67 (2.27) 28.83 (2.17) 31.67 (2.09) 
     
R
work
/R
free
b% Rigid Body 25.4 / 27.1 28.9 / 29.7 28.0 / 28.1 28.7 / 29.1 
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Data Collection DGJ_100uM DGJ_1mM 
Protein Fabrazyme Fabrazyme 
Space Group P3
2
21 P3
2
21 
Cell Constants, A° 90.38  90.38 216.89 90.08  90.08 216.25 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 
   
X-Ray Source NSLS - X6A NSLS - X6A 
Wavelength, A° 1.1 1.1 
Resolution (last shell) 50.0 - 2.4 50.00 - 2.15 
Unique Observations 40269 55988 
Completeness, % 
(last shell) 97.8 (97.5) 99.6 (99.1) 
Multiplicity (last shell) 3.7 (3.8) 11.0 (10.5) 
R
sym 
(last shell) 11.7 (52.0) 13.1 (92.6) 
I/σ
I 
(last shell) 12.03 (2.2) 21.0 (2.36) 
   
R
work
/R
free
b% Rigid Body 26.1 / 27.5 28.5 / 29.4 
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Table	  A.4:	  Pharmacological	  Chaperone	  Titrations	  –	  Wild	  Type	  –	  Glucose	  Cryoprotectant	  
 
Data Collection DGJ_0mM DGJ_10nM DGJ_100nM DGJ_1uM 
Protein Fabrazyme Fabrazyme Fabrazyme Fabrazyme 
Space Group P3
2
21 P3
2
21 P3
2
21 P3
2
21 
Cell Constants, A° 90.79  90.79 217.17 90.25  90.25 216.67 90.48  90.48 216.94 90.16  90.16 216.82 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
     
X-Ray Source NSLS - X6A NSLS - X6A NSLS - X6A NSLS - X6A 
Wavelength, A° 1.1 1.1 1.1 1.1 
Resolution (last shell)  50.00 - 2.10 50 - 2.00 50 - 2.10 
Unique Observations 19123 60646 70575 60359 
Completeness, % (last shell) 12.6 99.8 (100) 99.9 (100.0) 99.8 (99.6) 
Multiplicity (last shell) 1 7.6 (7.6) 11.0 (11.0) 7.3 (7.3) 
R
sym 
(last shell)  9.9 (95.0) 10.7 (84.3) 10.9 (82.4) 
I/σ
I 
(last shell)  22.67 (2.27) 28.19 (2.68) 20.24 (2.03) 
     
R
work
/R
free
b% Rigid Body  27.9 / 28.6 28.2 / 28.3 29.0 / 29.2 
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Data Collection DGJ_100uM DGJ_1mM DGJ_50mM 
Protein Fabrazyme Fabrazyme Fabrazyme 
Space Group P3
2
21 P3
2
21 P3
2
21 
Cell Constants, A° 90.42  90.42 216.69 90.23  90.23 216.92 90.67  90.67 217.14 
Cell Angles, ° 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
    
X-Ray Source NSLS - X6A NSLS - X6A NSLS - X6A 
Wavelength, A° 1.1 1.1 1.1 
Resolution (last shell) 50.0 - 2.0 50.0 - 2.15 50.0 - 2.0 
Unique Observations 68544 56296 70480 
Completeness, % 
(last shell) 97.5 (96.7) 99.0 (98.4) 99.4 (98.9) 
Multiplicity (last shell) 7.1 (7.0) 7.5 (7.5) 5.5 (5.6) 
R
sym 
(last shell) 8.7 (83.3) 10.3 (88.8) 10.6 (60.8) 
I/σ
I 
(last shell) 24.97 (1.98) 21.59 (2.08) 21.92 (2.40) 
    
R
work
/R
free
b% Rigid Body 27.9 / 28.2 28.6 / 29.6 27.8 / 28.2 
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Table	  A.5:	  Glucose	  Titrations	  
 
 Glucose 0.1mM Glucose 1mM Glucose 10mM Glucose 100mM Glucose 500mM 
Data Collection      
Protein Fabrazyme Fabrazyme Fabrazyme Fabrazyme Fabrazyme 
Space Group P3
2
21 P3
2
21 P3
2
21 P3221 P3221 
Cell Constants, A° 90.64  90.64 216.55 90.434  90.44 217.27 90.27  90.27 216.40 
90.485  90.485 
216.668 90.18  90.18 216.50 
Cell Angles, ° 90.00  90.00 120.00 90.000  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 90.00  90.00 120.00 
      
X-Ray Source NSLS - X6A NSLS - X6A NSLS - X6A NSLS - X6A In-House 
Wavelength, A° 0.97 0.97 0.97 0.97 1.54 
Resolution (last shell) 50.00 - 3.21 50.00 - 2.48 50.00 - 3.29- 50.00 - 3.33 50.00 - 3.32 
Unique Observations 17609 37352 16081 15772 15695 
Completeness, % (last 
shell) 100.0 (99.9) 99.9 (100.0) 99.3 (100.0) 100.0 (100.0) 99.3 (99.3) 
Multiplicity (last shell) 6.8 (6.6) 10.9 (11.2) 6.5 (6.5) 6.8 (6.8) 3.7 (3.8) 
R
sym 
(last shell) 28.6 (80.9) 15.3 (0.00) 25.6 (70.6) 28.8 (95.5) 18.7 (62.9) 
I/σ
I 
(last shell) 7.6 (2.14) 17.0 (2.04) 7.0 (2.06) 7.5 (2.00) 7.2 (2.07) 
      
R
work
/R
free
b% Rigid Body MR: 25.5/25.3 26.2/27.6 25.2/25.7 26.1/26.9 25.9/26.5 
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APPENDIX	  B	  
CRYSTAL	  SOAKS	  PREPARED	  BUT	  NOT	  COLLECTED	  
SB Hampton Kit # Resolution 
31 3.6A 
32 3.3A 
38 3.4 x 4.5A 
42 3.6A 
46 none 
51 none 
57 none 
61 4.1A 
63 none 
64 none 
65 6.4A 
66 3.4A 
67 4.5A 
68 3.9A 
69 none 
70 3.6A 
71 4.2A 
72 none 
73 4.0A 
74 6.8A 
75 4.0A 
76 3.6A 
77 none 
78 3.8A 
79 4.5A 
80 none 
82 none 
83 none 
84 none 
85 5.0A 
86 dropped 
87 none 
88 none 
89 none 
90 none 
91 none 
92 weak 
93 none 
94 weak 
95 none 
96 none 
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APPENDIX	  C	  
SILVER	  BULLET	  SOAK	  COMPOUNDS	  
#	   Conc	   Silver	  Bullets	  chemical	  name	   Molecular	  Formula	  
1	  (A1)	   0.33%	  w/v	   1,5-­‐Naphthalenedisulfonic	  acid	  disodium	  salt	   C10H6Na2O6S2	  
1	  (A1)	   0.33%	  w/v	   2,5-­‐Pyridinedicarboxylic	  acid	   C7H5NO4	  
1	  (A1)	   0.33%	  w/v	   3,5-­‐Dinitrosalicylic	  acid	   (O2N)2C6H2-­‐2-­‐(OH)CO2H	  
1	  (A1)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	  
	  	   	  	   	  	   	  	  
2	  (A2)	   0.25%	  w/v	   Benzidine	   C12H12N2	  
2	  (A2)	   0.25%	  w/v	   Nicotinamide	   C6H6N2O	  
2	  (A2)	   0.25%	  w/v	   Pyromellitic	  acid	   C10H6O8	  
2	  (A2)	   0.25%	  w/v	   Sulfaguanidine	   C7H10N4O2S	  
2	  (A2)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	  
	  	   	  	   	  	   	  	  
3	  (A3)	   0.25%	  w/v	   Gly-­‐gly	   NH2CH2CONHCH2COOH	  
3	  (A3)	   0.25%	  w/v	   Gly-­‐gly-­‐gly	   NH2CH2CONHCH2CONHCH2COOH	  
3	  (A3)	   0.25%	  w/v	   Gly-­‐gly-­‐gly-­‐gly	   NH2CH2CO(NHCH2CO)3OH	  
3	  (A3)	   0.25%	  w/v	   Pentaglycine	   NH2CH2CO(NHCH2CO)3NHCH2COOH	  
3	  (A3)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	  
	  	   	  	   	  	   	  	  
4	  (A4)	   0.25%	  w/v	   3,5-­‐Dinitrosalicylic	  acid	   (O2N)2C6H2-­‐2-­‐(OH)CO2H	  
4	  (A4)	   0.25%	  w/v	   4-­‐Aminobenzoic	  acid	   H2NC6H4CO2H	  
4	  (A4)	   0.25%	  w/v	   Salicylic	  acid	   2-­‐(HO)C6H4CO2H	  
4	  (A4)	   0.25%	  w/v	   Trimesic	  acid	   C6H3(CO2H)3	  
4	  (A4)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	  
	  	   	  	   	  	   	  	  
5	  (A5)	   0.33%	  w/v	   4-­‐Nitrobenzoic	  acid	   O2NC6H4CO2H	  
5	  (A5)	   0.33%	  w/v	   5-­‐Sulfosalicylic	  acid	  dihydrate	   HO3SC6H3-­‐2-­‐(OH)CO2H·∙2H2O	  
5	  (A5)	   0.33%	  w/v	  
Naphthalene-­‐1,3,6-­‐trisulfonic	  acid	  trisodium	  salt	  
hydrate	   C10H5Na3O9S3	  ·∙	  xH2O	  
5	  (A5)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	  
	  	   	  	   	  	   	  	  
6	  (A6)	   0.33%	  w/v	   2,6-­‐Naphthalenedisulfonic	  acid	  disodium	  salt	   C10H6(SO3Na)2	  
6	  (A6)	   0.33%	  w/v	   2,7-­‐Naphthalenedisulfonic	  acid	  disodium	  salt	   C10H6Na2O6S2	  
6	  (A6)	   0.33%	  w/v	   Anthraquinone-­‐2,6-­‐disulfonic	  acid	  disodium	  salt	   C14H6Na2O8S2	  
6	  (A6)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	  
	  	   	  	   	  	   	  	  
7	  (A7)	   0.33%	  w/v	   1,5-­‐Naphthalenedisulfonic	  acid	  disodium	  salt	   C10H6Na2O6S2	  
7	  (A7)	   0.33%	  w/v	  
Naphthalene-­‐1,3,6-­‐trisulfonic	  acid	  trisodium	  salt	  
hydrate	   C10H5Na3O9S3	  ·∙	  xH2O	  
7	  (A7)	   0.33%	  w/v	   PIPES	   C8H18N2O6S2	  
7	  (A7)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	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8	  (A8)	   0.25%	  w/v	   1-­‐Pentanesulfonic	  acid	  sodium	  salt	  monohydrate	   CH3(CH2)4SO3Na	  ·∙	  H2O	  
8	  (A8)	   0.25%	  w/v	   3,5-­‐Dinitrosalicylic	  acid	   (O2N)2C6H2-­‐2-­‐(OH)CO2H	  
8	  (A8)	   0.25%	  w/v	   3-­‐Aminosalicylic	  acid	   H2NC6H3-­‐2-­‐(OH)CO2H	  
8	  (A8)	   0.25%	  w/v	   Salicylamide	   2-­‐(HO)C6H4CONH2	  
8	  (A8)	   0.02	  M	   HEPES	  sodium	  pH	  6.8	   C8H17N2NaO4S	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APPENDIX	  D	  
	  
	  	   	   	   	   	  	   ISOTHERMAL	  CALORIMETRY	  DATA	  
	  
	   Preliminary	  Raw	  ITC	  Data	  and	  isotherm	  in	  10mM	  Phosphate	  Buffer	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Preliminary	  Raw	  ITC	  Data	  and	  isotherm	  in	  10mM	  Phosphate	  Buffer	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